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Cardiovascular diseases are leading causes of morbidity and mortality in industrialized countries. They 
are based on genetic and environmental factors and are associated with substantial abnormalities in 
metabolic and inflammatory pathways.1 Different etiological triggers, like arterial hypertension, myo-
cardial infarction, or valvular disease, ultimately all culminate in a phenotypcically identical form of 
end-stage disease, which is referred to as heart failure (figure 1). The prevalence of heart failure is 
estimated at 1-2% in the Western world, with an incidence that approaches 10 per 1000 persons per 
year.2 Although survival of patients with cardiovascular diseases has started to improve,3,4 mortality 
rates after onset of heart failure remain high. 
LIVER X RECEPTORS
Liver X receptors (LXRs) are nuclear hormone receptors that act as ligand-activated transcription fac-
tors.5 They are critically involved in cholesterol metabolism6 and their natural ligands are oxysterols; 
oxidized cholesterol derivatives.7 There are two known isoforms of LXRs; LXR-α (mainly expressed 
in liver, spleen, intestine, macrophages, heart and kidney) and LXR-β (expressed ubiquitously).8 LXRs 
form a heterodimer with the retinoid X receptor (RXR). This complex binds to specific parts of the ge-
nome called LXR response elements (LXREs). In the non-active state, the LXR/RXR complex is occupied 
by corepressor complexes (figure 2A). However upon ligand binding, the corepressor complexes are 
exchanged by coactivator complexes, which results in the transcription of specific target genes of LXR 
(figure 2B).
Over the last decade, research on LXRs was mainly focused on their role in cholesterol metabolism. 
It was discovered that LXRs play a crucial role in the process of ‘reverse cholesterol metabolism’; 
the efflux of cholesterol from peripheral tissues towards the liver for excretion.6 More recent studies 
show that LXRs also exert pleiotropic properties. They have been shown to attenuate proliferative 
pathways,9 blunt inflammatory responses,10 and influence the renin-angiotensin-aldosterone system 
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(RAAS).11 An extensive overview of LXRs and their potential role in cardiovascular disease is described 
in chapter 1.
SCOPE OF THIS THESIS
Metabolic and inflammatory pathways highly influence the onset and development of cardiovascular 
disease. Both pathways are controlled by complex mechanisms, in which LXRs play a critical role.12 
However, knowledge of the direct effects of LXRs on the cardiovascular system remains scarce. 
In this thesis, several models of cardiac remodeling and cardiac failure have been used to investigate 
the role of LXRs in the pathophysiology of these conditions. Chapter 1 provides an in-depth review on 
the role of LXRs in the cardiovascular system. In this review, we describe the potential role of LXRs in 
atherosclerosis, blood pressure homeostasis, and cardiac remodeling by summarizing recent literature 
on this topic combined with our findings described in the following chapters. Chapter 2 describes how 
we identified LXRs as negative regulators of the RAAS, the main system regulating blood pressure 
homeostasis. With this study we confirmed earlier studies describing LXR-α as a regulator of renin 
transcription.11 Chapter 2 describes the first long-term in vivo study focussing on LXR signalling in the 
RAAS. We further studied the role of LXRs in the cardiovascular system by activating LXRs in a model 
of cardiac remodeling (chapter 3). In vitro studies show that activation of LXRs attenuates hypertrophy 
in cultured cardiomyocytes. To corroborate these findings in vivo, abdominal aortic constriction (AC) 
was used as a pressure overload model to induce cardiac hypertrophy in wild-type and LXR-α-deficient 
(LXR-α-/-) mice. We show that also in vivo, LXR activation attenuates the development of LVH. Using 
the same model as in chapter 3, we studied the interaction of LXRs and statins in chapter 4. Statins 
are known to attenuate the development of LVH,13 but the molecular mechanism through which this 
effect is exerted is still not fully elucidated. In chapter 4 we show that LXRs play an essential role in 
this mechanism and that without LXR-α (LXR-α-/- mice) statins no longer exert their cardioprotective 
effects. In chapter 5 we explore the effects of LXR activation in a model of myocardial infarction. Here 
we show that also in this model of cardiac remodeling activation of LXRs improves cardiac function 
and attenuates LVH. Chapter 6 discusses the role of nuclear hormone receptors, including LXRs, in the 
RAAS. Several components of the RAAS (renin, angiotensinogen, angiotensin receptors) are discussed 
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with respect to their transcriptional regulation and the way nuclear hormone receptors affect these 
processes. The findings reported in this thesis are summarized in the final chapter ‘Summary and 
Future Perspectives’.
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Liver X receptors (LXRs) are key players in cholesterol and lipid metabolism. In the last decade, several 
pleiotropic functions have been discovered, that suggested that LXRs may be potential targets in in-
flammatory response, hypertension, and cell proliferation. This review focuses on the role of LXRs in 
the cardiovascular system, discussing their effects on the development of atherosclerosis, inflamma-
tory responses, cardiomyocyte hypertrophy, and cardiac remodeling.
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INTRODUCTION
Although liver X receptors (LXRs) were originally identified as key players in cholesterol and lipid me-
tabolism,1 numerous pleiotropic functions of LXRs have been revealed since.2 The importance of nor-
mal LXR functioning for maintaining homeostasis in many physiological processes is further strength-
ened by the observation that LXR functioning is associated with longevity.3 In this review we will 
discuss how LXR functioning, in both lipid metabolism and other physiological processes, affects the 
cardiovascular system.
Nuclear hormone receptors
LXRs are members of the nuclear hormone receptor family. Nuclear hormone receptors consist of a 
large group of nuclear receptors that exert a wide variety of actions.4 They directly bind to genomic 
DNA and act as transcription factors by binding onto specific elements in the DNA (hormone response 
elements; HREs), thereby regulating the transcription of genes downstream the HREs. Their natural 
ligands are small lipophilic molecules (e.g. hormones) or metabolic intermediates (sterols, prostaglan-
dins). Several reviews have recently been published that cover contemporary knowledge on nuclear 
hormone receptors.5,6,7 
Nuclear hormone receptors are grouped into a large superfamily and are thought to be evolutionary 
derived from a common ancestor. Evolutionary analysis of the receptors has led to a subdivision in six 
different subfamilies, based on their similarities in areas of structural homology.4 One of these sub-
families is formed by a large class of ex-orphan receptors, including LXRs, thyroid receptors, vitamin 
D receptors (VDRs), peroxisome proliferator activated receptors (PPARs), and retinoic acid receptors 
(RARs). Although these receptors are mostly known for their roles in growth, differentiation, metab-
olism, reproduction, and morphogenesis of higher organisms and humans, recent studies have de-
scribed several ancillary effects. For example, a large number of nuclear hormone receptors has been 
shown to influence the renin-angiotensin-aldosterone system (RAAS); the main regulator of blood 
pressure homeostasis.8 
LXRs: discovery, ligands, and mechanisms of action
LXRs were first identified in 1994 and 1995 by independent groups.9,10,11 Because their biological li-
gands were initially unknown, they were originally classified as “orphan receptors”. In the following 
years it was discovered that endogenous oxysterols (oxidized cholesterol derivatives) serve as activa-
tors of LXRs - LXRs were thus “deorphanized”.12 
LXRs form a heterodimer with the retinoid X receptor (RXR). This complex binds to specific parts of the 
genome called LXR response elements (LXREs). LXREs consist of direct repeats of the core sequence 
AGGTCA separated by 4 nucleotides, hence denoted DR4.11 In the non-active state, the LXR/RXR com-
plex is occupied by corepressor complexes. However upon ligand binding, the corepressor complexes 
are exchanged by coactivator complexes, which results in the transcription of specific target genes of 
LXR. The LXR/RXR complex is a “permissive heterodimer” that can be activated by ligands of either 
partner (as opposed to “nonpermissive heterodimers” that can also be formed with RXR, but are 
only activated by ligands specific for its binding partner). Ligand activation of LXRs can also result in 
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transcriptional regulation of genes that do not contain a LXRE. Through a process of trans-repression, 
LXR activation may inhibit the transcription of certain genes, e.g. proinflammatory cytokines.13 Fi-
nally, LXRs are capable of regulating gene transcription in a ligand-independent fashion.14 Activated by 
cAMP, LXRs have been shown to bind to a specific cAMP responsive element, called CNRE (cAMP nega-
tive responsive element). This responsive element, which is distinctly different from DR-4 elements, is 
found in the promoters of several cAMP responsive genes, such as c-myc, tyrosine aminotransferase, 
and renin. These modes of action all play a role in LXRs’ impact on CV disease. 
There are two known isoforms of LXR; LXR-α (NR1H3) and LXR-β (NR1H2).15 The two isoforms share a 
close homology and have approximately 77% identical amino acid sequences in both DNA- and ligand-
binding domains. The LXR-α isoform is predominantly expressed in cells and tissues that play a role 
in cholesterol metabolism (such as the liver, intestine, and in macrophages) but also in considerable 
quantities in organs less importantly involved in cholesterol metabolism, such as the kidney and the 
heart. The LXR-β isoform is expressed in all tissues examined.16 
CHOLESTEROL AND LIPID METABOLISM
Since lipid metabolism and lipid disorders are quintessential in CV disease, the role of LXRs in lipid 
metabolism is herein highlighted. When oxysterols were identified as potent LXR ligands,12 their role 
in cholesterol metabolism soon became evident. The creation of mice with genetic disruption of LXR-α 
(LXR-α-/- mice) showed that LXR-α is crucial in cholesterol clearance from tissues. When fed with a 
high cholesterol diet, LXR-α-/- mice exhibited a decreased metabolism of cholesterol to bile acids and 
a dramatic accumulation of cholesterol esters in the liver.1 Since these effects are far less pronounced 
in LXR-β-/- mice,17 it is assumed that LXR-α is the dominant isoform in so-called reverse cholesterol 
transport (RCT).
Target genes
One of the first genes identified as a LXR-α target gene is Cyp7a1, which encodes the rate-limiting 
enzyme in the synthesis of bile acid from cholesterol.18 The absence of hepatic Cyp7a1 expression in 
LXR-α-/- mice causes a near complete disability to metabolize cholesterol to bile acids, and this con-
tributes to the accumulation of cholesterol esters in the liver. Subsequent studies identified LXR as a 
regulator of the expression of ATP-binding cassette (ABC) membrane transporters, such as ABCA1 and 
ABCG1. These transporters mediate the efflux of cholesterol from cells (in the form of high-density 
lipoproteins [HDL] back to the liver to be excreted in the bile, the process known as RCT. In addition to 
this, LXRs are also important regulators of hepatic lipogenesis. LXRs regulate the expression of sterol 
regulatory element binding protein (SREBP)-1c;19 a transcription factor that regulates the expression 
of all genes involved in hepatic fatty acid biosynthesis, e.g. acetyl-CoA carboxylase (ACC), fatty acid 
synthase (FAS), and stearoyl-CoA desaturase (SCD). 
ATHEROSCLEROSIS
Development of atherosclerosis and role of lipids
Because of their eminent role in cholesterol metabolism, the potentially beneficial role of LXRs in the 
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treatment and development of atherosclerosis has been studied extensively. LXR activity is important 
during (almost) all stages of atheroma formation, and LXRs are therefore an attractive therapeutic tar-
get. Atherosclerosis is multifactorial, however, high plasma concentrations of cholesterol, particularly 
low-density lipoprotein (LDL), form a major risk factor.20 Early lesions consist mainly of monocyte-
derived macrophages, filled with cholesterol, that are formed after monocytes adhere to the dam-
aged vessel wall.21 They further differentiate into macrophages that exhibit massive accumulation of 
cholesterol (‘foam cells’). Progression of the lesion involves inflammatory processes: influx of T-cells, 
macrophages, and smooth muscle cells, production of cytokines. Death of the lipid-laden foam cells 
may lead to the formation of a necrotic core enclosed in a fibrous cap. The rupture of an advanced le-
sion can lead to thrombus formation that may occlude a vessel lumen, inducing ischemia in the heart, 
brain, or extremities, resulting in infarction.
Importance of reverse cholesterol transport (RCT)
The RCT is an endogeneous system to clear cholesterol from tissues, and is thought to be essential 
to prevent atherosclerosis. Patients that lack the gene encoding ABCA1, who have a defective RCT, 
develop accelerated atherosclerosis.22 LXRs are key mediators of the RCT. LXRs (and other nuclear 
hormone receptors) do not only influence cholesterol metabolism systemically but also regulate lipid 
homeostasis and inflammatory responses in macrophages, endothelial cells, and smooth muscle cells 
within the artery wall. LXRs are expressed abundantly in macrophages and are involved in the scav-
enger function of macrophages. LXRs in macrophages are activated by oxysterols that are produced 
in proportion to cellular cholesterol content.23 Furthermore, apoptotic cells in atherosclerotic plaques 
are internalized by macrophages, also initiating the RCT pathway, which protects the cell from lipid 
overload and its cytotoxic effects. When activated, LXRs stimulate expression of several genes involved 
in lipid metabolism en reverse cholesterol transport like ABCA1 and ABCG1. 
On a functional level, these mechanisms were confirmed by murine studies that showed that activa-
tion of LXR with synthetic ligands inhibits the development of atherosclerosis in apoE-/- and LDL-recep-
tor-/- mice.24,25 The significant induction of ABCA1 in atherosclerotic lesions of apoE-/- mice suggested 
that a direct effect of the LXR agonist on macrophages in the arterial wall could have contributed to 
the anti-atherosclerotic effect of the LXR ligand. Subsequent studies using bone marrow transplan-
tations confirm the key role of macrophages and LXR in this process: transplantation of apoE-/- and 
LDL-receptor-/- mice with bone marrow from LXR-/- mice resulted in an increase of atherosclerosis.26 
Mechanistic studies showed that the anti-atherosclerotic effects of LXR activation in macrophages 
seem to be largely attributable to the anti-inflammatory effects of LXR activity27 (and reviewed by28). 
LXR and the inflammatory response
Macrophages are key players in inflammatory processes, including in lipid metabolism and athero-
sclerosis.28 Working as scavengers of pathogens and apoptotic cells, they coordinate inflammatory 
responses by the release of cytokines and chemokines. The expression of these inflammatory media-
tors is, like with LXRs, mediated by oxidized low-density lipoprotein (oxLDL) particles. Lipid disorders 
and other CV risk factors, like diabetes, lead to the accumulation of oxLDL particles in macrophages 
and increased susceptibility to atherosclerosis.29 This leads to subsequent activation of LXRs, which 
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should be regarded as an endogenous response to neutralize the increased lipid and inflammatory 
stimuli. LXRs have been shown to inhibit expression of genes involved in the innate immune response 
in activated macrophages in vitro.27 In vivo, activation of LXRs leads to diminished inflammatory gene 
expression also, whereas LXR-/- mice exhibit enhanced reactions to inflammatory stimuli in a murine 
model of contact dermatitis.30 Similarly, LXR-/- mice are highly susceptible to infection when challenged 
with the gram-positive bacteria Listeria monocytogenes.31 LXR-/- mice were unable to recover from an 
infection with L. monocytogenes and did not survive the challange, whereas wildtype mice were able 
to effectively clear the same dose of L. monocytogenes.
The anti-inflammatory capacity of LXRs is an important feature for the scavenger function of mac-
rophages. When apoptotic cells are internalized by macrophages, inflammatory responses are not 
appropriate. The cholesterol derivatives produced by these apoptotic cells activate LXRs, resulting in a 
repression of inflammatory gene expression. When pathogens are internalized however, an inflamma-
tory response is warranted. Since most pathogens lack cholesterol derivatives (the natural ligands for 
LXRs), they are not likely to activate LXRs and thus repress immune responses.
It is believed that a major part of the anti-inflammatory effects of LXRs are mediated via nuclear 
factor-kappa (NF-κ)B.27 LXR agonists repress the expression of multiple NF-κB target genes, although 
the upstream signaling pathway controlling NFκB activation is not altered by LXR agonists, suggesting 
that LXR agonists may exert their effects downstream of NFκB binding to DNA.32 In contrast to NF-κB, 
LXR activation leads to increased expression of tumor necrosis factor (TNF)-α. Transfection analysis 
and inhibitor studies demonstrated that the TNF-α promoter contains an LXRE, which makes it a direct 
target for transactivation by LXR/RXR heterodimers.33 This seems in contrast with the anti-inflamma-
tory capacities of LXR signaling. In this process however, the absence of the other primary cytokines 
normally associated with inflammation suggests that LXR activation does not elicit a generalized pro-
inflammatory response. In addition to the regulation of the specific inflammatory markers NFκb and 
TNF-α, LXR activity protects macrophages from apoptotic signalling pathways.34 
Genetics
In patients, there is a correlation between the severity of coronary atherosclerosis and the blood 
cellular LXR-α genomic profile.35 Human blood mononuclear cells show a gradual increase in LXR-α 
gene transcription with respect to severity of coronary occlusion in patients suffering from coronary 
heart disease. This seems in contrast with the observed protective role of LXR-α in the development 
of atherosclerosis. However, functional genomics of the LXR-α mRNA revealed three critical mutations 
in the ligand binding domain of the blood cellular LXR-α gene in these patients.36 In vitro studies show 
that these mutations render the LXR-α protein unable to bind to its natural ligands. These studies sug-
gest that humans having a mutated LXR-α gene may develop a predisposition towards coronary heart 
disease. A defective LXR-α gene can affect cardiac function through several mechanisms.
EFFECTS OF LXRS BEYOND LIPIDS: CARDIAC REMODELING 
Cardiac (or ventricular) remodeling is the common term used for pathophysiological changes in size, 
shape, and function of the heart after cardiac injury.37 Remodeling may occur after myocardial in-
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farction, in response to chronic pressure overload (aortic stenosis, hypertension), volume overload 
(valvular regurgitation), inflammatory heart muscle disease (myocarditis), congenital heart disease 
or genetic cardiomyopathy. The initial remodeling response after cardiac injury is considered to be 
beneficial and is aimed to cope with the increased loading and work load of the heart. The cellular 
re-arrangement of the ventricular wall and activated neurohormonal systems results with maintained 
(or improved) cardiac output. However, the very adapative mechanisms that are initially beneficial 
become adverse on the long term and progressive remodeling occurs, which ultimately may lead to 
heart failure. The time course and the extent of remodeling are influenced by many factors, such as 
the severity of the insult, secondary events (recurrent ischemia or infarction), neurohormonal activa-
tion, hemodynamic load, and genetic factors.
Recently, we and others showed that activation of LXRs in a model of pressure overload leads to at-
tenuated cardiac hypertrophy.38,39 The exact mechanism underlying this effect is still unclear, but it 
has been shown that LXRs are involved in several factors that influence the development of cardiac 
remodeling, such as inflammatory responses and the RAAS.
Inflammatory responses
Injury to the heart triggers a reparative response that activates the innate immune system, resulting 
in an inflammatory reaction. Central player in both hypertrophy and inflammatory responses resulting 
from cardiac injury is NFkB.40 Although the exact role of NFκB in cardiac inflammatory responses is still 
under investigation, it has been shown that blocking NFκB activity in a rat model of myocarditis pre-
vents the progression of the cardiac inflammation.41 Also in patients, increased activation of NFκB is 
related to inflammatory processes in myocarditis.42 In addition to this, NFκB has proven to be a crucial 
player in the development of cardiac remodeling.43
So far, little is known about the effects of LXR activation on cardiac inflammatory responses. However, 
LXR has been identified as a negative regulator of NFκB.27 This might explain why activation of LXR 
results in attenuated cardiac remodeling in a model of cardiac pressure overload.39 Indeed, Wu et al. 
showed that in cultured cardiomyocytes, activation of LXRs by a synthetic agonist suppressed both 
angiotensin II and lipopolysaccharide induced upregulation of NFκB activity, resulting in decreased 
expression levels of TNF-α, interleukin-6, and monocyte chemotactic protein-1.38 After the challenge 
with angiotensin II or lipopolysaccharide, the hypertrophic response of these cultured cardiomyo-
cytes was attenuated when the cells were treated with the LXR agonist. We confirmed these data in 
neonatal rat derived ventricular cardiomyocytes and in the mouse atrial cell line HL-1 challenged with 
endothelin-1 or angiotensin II.39 In both cell types, treatment with a LXR agonist attenuated the endo-
thelin-1 or angiotensin II induced hypertrophic response. Continuous research will have to determine 
the exact role of LXR induced blunting of NFκB signaling and how this affects both inflammatory and 
hypertrophic responses in cardiomyocytes.
The RAAS
The RAAS plays a central role in the development of cardiac remodeling. Therefore, treatment strate-
gies targeting the RAAS, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin recep-
tor blockers (ARBs), and aldosterone receptor antagonists, have been very beneficial in the preven-
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tion of progressive remodeling and heart failure.44 Numerous nuclear hormone receptors are able to 
influence RAAS activation, among which LXR45 and PPAR-γ.46 The important role of LXR in the RAAS 
has been substantiated by several in vitro and in vivo observations. First, it was shown by Tamura 
et al. that LXR-α functions as a cAMP-responsive regulator of renin in As4.1 cells (cells resembling 
juxtaglomerular [JG] cells, which produce renin).14 LXR-α interacts with a specific DNA element in the 
renin promoter, a CNRE. These findings were confirmed in an in vivo study, showing that also in mice 
LXR-α (and LXR-β) binds to the CNRE, and mice deficient for LXRs lose their capacity to up-regulate 
renin under β-adrenergic stress.47 LXR-α and renin show strict co-localization in the JG cells. Single ad-
ministration of a LXR agonist caused increased renin transcription within a few hours after administra-
tion. However, this was transient and returned to normal within hours. Recently, a role for LXR-α was 
reported in the differentiation of mesenchymal cells into JG cells.48 Still, it remained unclear whether 
LXR-α is a negative or positive regulator renin in vivo.
Using a long-term murine model of RAAS activation (isoproterenol infusion or 7 days), we have shown 
that concomitant activation of LXR leads to diminished mRNA expression of several RAAS compo-
nents, including renin, but also ACE and angiotensin type I receptor (AT
1
R) mRNA expression.45 Using 
LXR-α-/- mice, we confirmed in our models that the isoproterenol-induced RAAS activation is LXR-α 
dependent. These findings were in line with an in vitro study of Imayama et al., who demonstrated 
LXR to be a negative regulator of AT
1
R expression in cultured vascular smooth muscle cells.49 On the 
other hand, Leik et al. showed that LXR activation by GW3965 leads to a transient increase in vascular 
gene expression of the angiotensin type I receptor, which decreased over time.50 These findings in fact 
resemble the reported short-term increase of renin transcription after a single dose of T09 (reported 
by Morello et al.47) and the decrease of renin gene expression we found after a long-term period of LXR 
activation.45 For both AT
1
R and renin transcription, it seems that LXR activation results in a transient 
increase, followed by gradual and sustained decrease over time at a transcriptional and translational 
level. This hypothesis is supported by the observation by Leik et al. and our group; that long term 
treatment with a LXR agonist results in significant reductions of blood pressure, although this has not 
unequivocally been linked to the level of RAAS activation. All together there are convincing data to 
show that LXRs regulate renin transcription and that, in long term in vivo experiments, LXR activation 
is associated with inhibition of the RAAS. 
SUMMARY AND FUTURE PERSPECTIVES
Over the last decade, the knowledge on LXR functioning in (patho)physiological conditions has in-
creased intensively. As inhibitors of inflammatory responses, hypertension, cardiomyocyte hypertro-
phy, etc., LXR agonists may present attractive remedies in the treatment of several cardiovascular 
diseases. The stimulatory effect of LXR activation on SREBP-1c forms a major challenge in the develop-
ment of LXR-based therapeutics; increased SREBP-1c activity leads to hypertriglyceridemia and fatty 
liver (steatosis hepatis). The successful development of LXR-based therapeutics requires strategies 
to exploit the beneficial aspects of LXR activation while avoiding these unwanted side effects. So far, 
attempts to limit increases of hepatic and plasma triglycerides in response to LXR-agonist treatment 
remain unsuccessful.51 
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The main challenge remains to exploit these beneficial properties of LXRs while retaining side affects 
of LXR activation, such as hypertriglyceridemia and steatosis hepatic. So far, the development of iso-
form, tissue, or gene specific LXR agonists has been proposed as potential solutions for these un-
wanted side effects.52 
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Liver X receptor (LXR)-α is a pivotal player in reverse cholesterol metabolism. Recently, LXR-a was 
implicated as an immediate regulator of renin expression in a cAMP-responsive manner. To determine 
whether long-term LXR-α activation affects activation of the renal and cardiac renin–angiotensin–al-
dosterone system (RAAS), we treated mice with T0901317 (T09, a specific synthetic LXR agonist) in 
combination with the RAAS inducer isoproterenol (ISO). LXR-α-deficient (LXR-α-/-) and wildtype (WT) 
C57Bl/6J mice were treated with ISO, T09 or both for 7 days. Low-dose ISO treatment, not associated 
with an increase in blood pressure, caused an increase in renal renin mRNA, renin protein and ACE 
protein in WT mice. WT mice treated with both ISO and T09 had decreased renal renin, ACE and AT
1
R 
mRNA expression compared with mice treated with ISO only. Cardiac ACE mRNA expression was also 
reduced in the hearts of WT mice treated with ISO and T09 compared with those treated with ISO 
alone. The transcriptional changes of renin, ACE and AT
1
R were mostly absent in mice deficient for 
LXR-α, suggesting that these effects are importantly conferred through LXR-α. In conclusion, LXR-α 
activation blunts ISO-induced increases in mRNA expression of renin, AT
1
R and ACE in the heart and 
kidney. These findings suggest a role for LXR-α in RAAS regulation.
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INTRODUCTION
Liver X receptors (LXRs) are nuclear hormone receptors that act as transcription factors. As such, LXRs 
regulate the expression of genes involved in cholesterol and fatty acid metabolism.1 In the liver, LXRs 
regulate expression of genes involved in bile acid and cholesterol metabolism, similar to sterol regula-
tory element binding protein (SREBP)-1c, which stimulates lipogenesis, and many other downstream 
genes.2 In the macrophages, gut and other cell types and tissues, LXRs have a crucial role in ‘reverse 
cholesterol transport,3 thereby stimulating the efflux of cholesterol from the peripheral tissue to 
the liver. Two different, yet highly homologous isoforms of LXR have been described, namely LXR-α 
(NR1H3) and LXR-β (NR1H2). Both LXRs heterodimerize with the retinoid X receptor (RXR) and bind 
to a DR-4 response element in the promoter of target genes.4 Natural ligands for LXRs are oxysterols, 
but strong synthetic agonists such as T0901317 (T09) and GW3965 have been developed. Although 
LXR-b is ubiquitously expressed, LXR-α is expressed mainly in the liver, adipose tissue, macrophages, 
intestine, spleen, kidney and heart.5,6 
In the kidney, LXRs are specifically expressed in renin-producing juxtaglomerular (JG) cells.7 In JG cells, 
renin transcriptional and translational control is meticulously regulated at multiple levels.8 The hor-
mone renin is the rate limiting step in the renin–angiotensin–aldosterone system (RAAS), which is 
the most critical regulator of blood pressure and salt-volume homeostasis in physiological and patho-
physiological conditions. LXRs were shown to regulate renin expression in vivo, suggesting a cross talk 
between the RAAS and lipid metabolism.7 It has been reported that LXRs regulate renin gene expres-
sion in a ligand-independent manner by interacting with a specific responsive element in the renin 
promoter, known as cAMP-negative response element (CNRE).7 However, it has also been shown that 
treatment of rats with the synthetic LXR agonist GW3965 interferes with angiotensin II-mediated pres-
sor responses.9 These two observations suggest that a cross talk between (ligand-dependent) LXR ac-
tivation and (ligand-independent?) RAAS activation exists, but it remains unknown whether long-term 
LXR stimulation modulates RAAS activity, and if so, what enzymes/peptides of the RAAS are affected 
by LXR stimulation. To determine which enzymes/peptides of the RAAS are affected by LXR activation, 
and whether LXR exerts stimulatory or rather inhibitory effects on the RAAS, we treated LXR-α defi-
cient (LXR-a-/-) and wildtype (WT) mice with the cAMP releasing β
1
-adrenergic agonist isoproterenol 
(ISO) in the absence or presence of the synthetic LXR agonist T09.
METHODS
Animals and housing conditions
All experiments were approved by the local Committee on Animal Experimentation and were con-
ducted under international guidelines on animal experimentation. Male C57BL/6J WT mice were ob-
tained from Harlan at the age of 10 weeks. LXR-α-/- mice on C57BL/6J background were generated by 
Deltagen (Redwood City, CA, USA), as described previously.10 During the entire experiment, animals 




Mice (groups consisted of n=7–9) were fed either standard laboratory chow or chow supplemented 
with the synthetic LXR agonist T09 (50mg/kg per day, Cayman Chemicals, Ann Arbor, MI, USA). This 
dose was previously shown to cause a strong, sustained activation of LXRs in vivo.11 ISO (10mg/kg per 
day) was administered as a continuous infusion through an osmotic pump (Alzet, Maastricht, The 
Netherlands; Model 1002). This dose was chosen because it causes a strong increase in renal renin 
expression and plasma renin activity.7 Pumps were inserted subcutaneously in the left flank under 
sterile conditions, while the mouse was anesthetized with isoflurane (2% in O2). Control animals and 
animals treated with only T09 received a saline-filled (NaCl 0.09%, vehicle) pump. After 7 days, body 
weight (BW) was determined, mice were anesthetized (as described) and a microtip pressure trans-
ducer (Millar Instr., Houston, TX, USA) was inserted into the right carotid artery. After a 5-min period 
of stabilization, heart rate (HR) and arterial systolic blood pressure (SBP)/diastolic blood pressure were 
recorded. Subsequently, animals were killed by cardiac puncture to aspirate blood. The heart (left 
ventricle), kidneys and liver were excised. All collected tissues were snap frozen in liquid nitrogen and 
stored at -80°C for RNA and protein isolation and biochemical analysis.
RNA analysis
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Total RNA from cells or tissues was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). 
cDNA synthesis was performed using standard methods. Briefly, first strand cDNA was prepared using 
random primer mix and subsequently used (50 ng per reaction) as a template for quantitative real-
time reverse-transcriptase PCR (qRT-PCR). mRNA levels were expressed in relative units on the basis 
of a standard curve obtained from serial dilutions of a calibrator cDNA mixture. All PCR results were 
normalized to β-actin mRNA levels. qRT-PCR primers used for β-actin were as follows: sense CGAGC-
GTGGCTACAGCTTCA, antisense AGGAAGAGGATGCGGCAGTG; for renin: sense ACCTTCAGTCTCCCAA-
CACG, antisense CTTTGTGAATACGCCCC ATT; for ACE: sense TGAGAAAAGCACGGAGGTATCC, antisense 
AGAGTTTTGAAAGTTGCTCACATCA; and for AT
1
R: sense CCATTGTCCACCCGATGAAG, antisense TGCAG-
GTGACTTTGGCCAC.
Western blot
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Protein was isolated by homogenizing ~100 mg of frozen tissue in 1ml of radioimmunoprecipitation 
assay buffer (0.5% sodium deoxycholate, 0.1% SDS, 1% Igepal ca-630 in 1xPBS) supplemented with 
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). After centrifugation at 14 000 
r.p.m. for 20 min at 4°C, the supernatant was collected and protein concentrations were determined 
using the DC assay (Bio-Rad, Veenendaal, The Netherlands) with a bovine albumin standard. SDS sam-
ple buffer was added to 20 mg of protein and samples were denaturized by heat at 99°C for 5 min. 
Proteins were separated by SDS-PAGE (Thermo Scientific, Breda, The Netherlands), and transferred to 
PVDF membranes (Bio-Rad). Blots were incubated overnight in antibodies for renin (1:750, kindly pro-
vided by Dr. Tadashi Inagami, Vanderbilt University School of Medicine, Nashville, TN, USA) and ACE 
(1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in milk. All western blot results were 
normalized to β-actin protein levels (1:20.000 Sigma-Aldrich, Zwijndrecht, The Netherlands).
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Cell culture of Calu-6 cells
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
The human renin-expressing Calu-6 cell line was obtained from the American Type Culture Collection 
(ATCC no. HTB- 56) and grown at 37°C in humidified air with 5% CO
2
 in Eagle’s minimal essential me-
dium (EMEM), supplemented with 2mM L-glutamine, nonessential amino acids and 10% fetal bovine 
serum (FBS). After overnight starvation (EMEM containing 0.1% FBS), cells were incubated with either 
solvent (1% DMSO), 8-Br-cAMP (1 mM, Sigma-Aldrich), T09 (3 mM, Cayman Chemicals) or both cAMP 
and T09 for 6 h.
Electrophoretic mobility shift assays
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Electrophoretic mobility shift assays (EMSAs) were performed with 32P-labeled double-stranded oli-
gonucleotide probes (Amersham Biosciences, Roosendaal, The Netherlands). Binding reactions were 
performed for 30 min at room temperature in Gel Shift Assay Core Systems (Promega, Leiden, The 
Netherlands), using 10 mg nuclear protein extracts. Nuclear extracts were isolated from human renin 
expressing Calu-6 cells treated with cAMP, T09 or both (as described) and from WT mice and LXR-a-/- 
mice. For neutralization studies, samples were coincubated with a 100-fold molar excess of unlabeled 
probe and anti-LXR-a mouse monoclonal antibody (Perseus Proteomics, Tokyo, Japan) for an addition-
al 15 min. After incubation, samples were separated on a 6% polyacrylamide gel and electrophoresed 
in 1x trisborate EDTA buffer for 3 h at 180 V. After electrophoresis, the gel was dried and exposed to 
autoradiography film overnight at -80°C. The sense oligonucleotide sequence is: CTAACTTGGTCTCA-
CAGGCTAGAA (CNRE).
Plasma cholesterol
Plasma cholesterol was determined using a commercial kit (Human Diagnostics Worldwide).
Statistical analysis
Measured values are presented as means±s.e.m., unless stated otherwise. Statistical analysis was per-







Control ISO T09 ISO + T09 control ISO T09 ISO + T09
Heart rate (bpm) 481 ± 23 535 ± 41 484 ± 19 446 ± 56 417 ± 25‡ 535 ± 23 524 ± 34 511 ± 15
HW/BW 5.77 ± 0.1 6.71 ± 0.1*6 .07 ± 0.1 7.44 ± 0.1*,† 4.02 ± 0.2‡4 .76 ± 0.1*,‡ 4.44 ± 0.1‡5 .27 ± 0.1*,†,‡
KW/BW 13.12 ± 0.1 12.68 ± 0.1 13.71 ± 0.1 13.28 ± 0.1† 15.47 ± 0.5‡ 14.40 ± 0.3‡ 16.31 ± 0.4‡ 13.80 ± 0.2*
LW/BW 56.05 ± 0.9 53.85 ± 1.3 84.06 ± 1.0* 74.09 ± 1.6* 48.53 ± 1.6‡ 49.14 ± 1.7‡ 57.53 ± 2.6*,‡ 57.78 ± 1.2*,†,‡




Body and organ weights, effects of T09
Mice were treated with ISO, T09 or both for 7 days. We chose the dose of ISO, so that it would not in-
crease HR or blood pressure. In WT mice, SBP was 103±4mmHg with saline infusion and 114±11mmHg 
with ISO infusion. HR was identical between groups. In WT mice, HW/BW ratios were significantly in-
creased in mice treated with ISO or ISO+T09 (table 1). As expected, T09 treatment caused a significant 
increase in liver weights (LWs) (LW/BW ratios), plasma cholesterol levels and hepatic SREBP-1c mRNA 
levels (data not shown). These data show that the dosing of T09 indeed resulted in LXR activation. In 
LXR-α-/- mice, the HW/BW ratio was lower compared with that in WT mice. However, in both geno-
types, a significant increase was found in the HW/BW ratio after treatment with either ISO alone or 
ISO+T09. The LW/BW ratio was also significantly lower in LXR-α-/- mice, but both genotypes showed 
an increase in LW after T09 (T09 alone or ISO±T09) treatment. As expected, this increase was more 
pronounced in WT mice than in LXR-α-/- mice (142 and 135%; P=0.000 and P=0.000, respectively, in WT 
as opposed to 119 and 119%; P=0.010 and P=0.006 in LXR-α-/- mice, T09 and ISO+T09, respectively). 
Increases in cholesterol levels after treatment with either T09 alone or both ISO+T09 were also more 
pronounced in WT mice than in LXR-α-/- mice. On the other hand, KW/BW ratios were significantly 
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higher in LXR-α-/- mice than in their WT littermates, but not in ISO+T09-treated animals.
T09 decreases renal renin, ACE and AT1R mRNA in WT mice, but not in LXR-α
-/- mice
Renal mRNA was isolated and gene expression of renin, ACE and the AT
1
R was assessed by qRT-PCR. 
Renal renin mRNA expression was increased in WT mice treated with ISO compared with saline-in-
fused controls (control: 0.74±0.17 vs ISO: 3.36±0.97, P=0.018; figure 1A). Cotreatment with both ISO 
and T09 showed that the ISO-induced increase in renin gene expression could be completely abolished 
by T09 treatment (0.59±0.28, P=0.012 vs ISO), whereas treatment with T09 alone did not affect renin 
mRNA expression (0.96±0.30, P=0.993 vs control). Interestingly, in LXR-α-/- mice, no effect of ISO treat-
ment was found on renal renin expression. Renin mRNA levels were significantly lower in ISO-treated 
LXR-α-/- mice than in ISO-treated WT mice. Similar findings were seen in renal ACE and AT
1
R mRNA 
and expression (see figure 1B and C). In WT mice, ISO+T09 treatment resulted in lower ACE and AT
1
R 
mRNA expression than did ISO treatment. Again, this was not observed in LXR-α-/- ice. In fact, ACE 
mRNA levels were higher in LXR-α-/- mice treated with ISO+T09 than in WT mice treated with ISO+T09 
(figure 1B). AT
1
R mRNA levels were lower in LXR-α-/- mice treated with ISO or T09 compared with the 
expression in WT mice after the same treatment (figure 1C). The transcriptional changes were paral-
leled by changes in protein expression of renal renin and ACE, which also remained unaffected by ISO 
treatment in LXR-α-/- mice, whereas in WT mice, ISO treatment significantly increased both renal renin 
and ACE protein levels (figure 2). Again, in WT mice, ISO induced renal protein expression of renin and 
ACE was blunted by cotreatment with T09.
T09 decreases cardiac ACE mRNA in WT mice, but not in LXR-α-/- mice
In WT mice, cardiac ACE mRNA levels were significantly lower in ISO+T09-treated animals compared 
with animals treated with ISO alone (figure 3A). In LXR-α-/- mice, treatment with ISO and/or T09 did not 
affect ACE mRNA expression and ACE mRNA expression was lower in ISO-treated LXR-α-/- mice than in 
WT mice. Cardiac AT
1
R mRNA expression was not altered in WT mice after ISO and/or T09 treatment, 
but again, AT
1
R mRNA expression was lower in ISO- and ISO+T09-treated LXR-α-/- mice compared with 
WT mice treated with ISO or ISO+T09 (figure 3B).
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T09 blunts affinity of LXR to CNRE
To corroborate our observations that LXR-α is responsible for the ISO-induced activation of the RAAS, 
we performed an EMSA to assess the affinity of LXR-α to the CNRE (a responsive element in the re-
nin promoter that was previously shown to bind LXR-α12). We used (1) nuclear protein extractions of 
human renin-expressing Calu-6 cells, treated with cAMP, T09 or both and (2) renal nuclear protein 
extracts of all experimental groups to compare WT with LXR-α-/- mice. figure 4A shows a specific shift, 
indicative of LXR-a binding to the CNRE. This shift is largely abolished by coincubation with excess un-
labeled CNRE (100M cold probe, lane 2) or by a specific anti-LXR-α antibody (anti-LXR-α antibody, lane 
4) but not by an aspecific antibody (IgG, lane 3). In figure 4B, it is shown that affinity of LXR to CNRE 
was increased when Calu-6 cells were treated with cAMP (lane 2). On the other hand, T09 caused a 
decrease in binding affinity to CNRE (lane 3), whereas coincubation with both cAMP and T09 restored 
the shift to control values (figure 4B, lane 4). In figure 4C, EMSA results from renal nuclear lysates are 
shown. In WT mice, an increase in LXR-α-CNRE affinity was found under ISO treatment (lane 3 com-
pared with lane 1); it was observed that this increase was blunted after additional treatment with T09 
(lane 7). However, in LXR-α-/- mice, no differences were found between the experimental groups (lanes 
2, 4, 6 and 8). LXR-α-CNRE affinity was found to be more pronounced in WT mice as compared with 
LXR-α-/- mice. In figure 4D, it is shown that the shift in renal lysates is abolished with excess unlabeled 
probe and neutralizing antibody. figure 4E shows morphometric analysis of the results in figure 4C.
DISCUSSION
We report that activation of LXR with the specific agonist T09 leads to a decrease in renal and cardiac 
RAAS activation due to ISO infusion. The LXR-α agonist T09 blunts ISO induced increases in renin, ACE 
and AT1R expression in vitro and in vivo, and competes with the binding of LXR-α to the CNRE in the 
renin promoter. The observed effects are completely absent in LXR-α-/- mice, suggesting LXR-α depen-
dency. On the basis of these data, we postulate that LXR agonists may serve as inhibitors of the RAAS. 
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We recently discussed the potential profound modulatory effects of nuclear hormone receptors on 
the RAAS.13 We now extent this hypothesis by showing that LXR activation inhibits transcription of 
RAAS components in the kidney and the heart. The ISO-induced activation of the RAAS was observed 
at a transcriptional level by the increase in renal renin and ACE mRNA. Activation of LXR by T09 treat-
ment resulted in decreased transcriptional levels of renin, ACE and AT
1
R mRNA. Recently, LXR-α was 
denoted as a cAMP-dependent regulator of renin.12 Morello et al.7 showed that LXR-α regulates renin 
transcription in vivo. LXR-α-/- mice (and LXR-α/β double knock-out mice) were unable to regulate renin 
transcription upon ISO stimulation in contrast to LXR-β-/- mice. This renders LXR-α as a cAMP-depen-
dent regulator of renin, whereas LXR-β seems to act more as a constitutive regulator of renin. This 
study portends that long-term treatment with T09 rather inhibits renin expression, and expression 
of other enzymes/proteins of the RAAS in the heart and kidneys. Our finding that T09 competes with 
the binding of LXR-α to the CNRE provides evidence for a transcriptional regulation. The transcrip-
tional regulation of ACE is largely unknown, whereas regulation of AT
1
R is tight, complex and well 
described.14 Our findings of decreased renal AT
1
R mRNA expression are in line with those of Imayama 
et al., 15 who demonstrated LXR to be a negative regulator of AT
1
R in cultured vascular smooth muscle 
cells. On the other hand, Leik et al. showed that LXR activation by GW3965 leads to a transient in-
crease in vascular gene expression of the AT
1
R, which decreased over time (measured over an 8-h 
period). These findings may resemble the reported initial increase in renin transcription single dose 
of T09 (reported by Morello et al.7) and the decrease in renin gene expression that we found after a 
long-term period of LXR activation. Therefore, for both AT
1
R and renin transcription, it seems that LXR 
activation results in a transient increase, followed by gradual and sustained decrease over time at the 
transcriptional and translational levels. 
If long-term activation of LXR results in decreased transcription levels of RAAS components, it is strik-
ing that LXR-α-/- mice do not show increased mRNA levels of these RAAS components, neither on a 
basal level nor after ISO treatment. To explain this apparent discrepancy, in this study, we propose a 
model of a ‘classical’ and an ‘alternative’ LXR-α pathway (figure 5). The classical pathway is entered 
upon binding of a specific ligand (oxysterols, T09), subsequent heterodimerization with RXR and bind-
ing of a DR4 element, initiating transcription of genes, such as SREBP-1c and ATP-binding-cassette 
(ABC) transporters. In the alternative pathway, LXR-α is activated in a different manner, in this study 
with cAMP, which may lead to phosphorylation. However, we do not know what specific mechanism is 
operative herein. The long-term treatment with T09 may ‘push’ all LXR-α toward the classical pathway, 
leaving no LXR-α to enter the alternative route. In support of this observation, we observed that with 
all of our perturbations (ISO, T09, combination), the transcript levels of LXR-α remain stable (data not 
shown). 
This study is the first to report the regulatory role of LXR on long-term RAAS gene and protein expres-
sion. T09 treatment led to sustained suppression of RAAS genes, leading to decreased protein produc-
tion of both renin and ACE, as compared with protein levels after ISO treatment alone. Although we 
found effects of LXR activation on both mRNA and protein levels, these changes in RAAS activation 
were not translated into significant changes in blood pressure. As we initially intended to study the 
role of LXR on a transcriptional level, we chose a dose of the β
1
adrenergic agonist ISO that does acti-
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vate renin transcription, yet reportedly does not cause hypertension. As we were in the normotensive 
range, this potentially explains why we did not observe any effects of LXR treatment on blood pres-
sure. In experiments conducted by Leik et al.,9 changes in blood pressure were only found in animals 
treated with doses of angiotensin II known to cause hypertension. It remains to be proven whether 
LXR activation has a role in blood pressure regulation, but given the observed effects on (renin, ACE, 
AT1R) gene expression, we hypothesize LXR may have a role in this. We show that LXR activation leads 
to decreased RAAS activation, suggesting a cross talk between the classical and an alternative pathway 
of LXR signaling. Activation of LXR leads to marked and sustained inhibition of ISO induced RAAS activ-
ity in the heart and kidney. On the basis of our observations, we hypothesize that LXR activation might 
provide a novel strategy in the treatment approach for several disorders, including metabolic disorders 
and cardiovascular disease.
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Liver X receptor (LXR) is a nuclear receptor regulating cholesterol metabolism. LXR has also been 
shown to exert anti-proliferative and anti-inflammatory properties. In this study, we evaluated the 
effect of LXR activation on cardiac hypertrophy in vitro and in vivo. Treatment with the synthetic LXR 
agonist T0901317 (T09) attenuated the hypertrophic response of cultured cardiomyocytes to endo-
thelin-1 almost to control levels. siRNA interference showed that this effect was indeed LXR specific. To 
corroborate these findings in vivo, abdominal aortic constriction (AC) was used as a pressure overload 
model to induce cardiac hypertrophy in wildtype and LXR-α-deficient (LXR-α-/-) mice. In wildtype mice, 
T09 treatment resulted in a decrease of cardiac wall thickening 4 and 7 weeks after AC. Also, after 7 
weeks of AC, mean arterial blood pressure and left ventricular weight/body weight (LVW/BW) ratios 
were decreased in T09 treated mice. These effects were not observed in LXR-α-/- mice, indicating that 
the beneficial effect of LXR activation on cardiac hypertrophy is attributable to the LXR-α isoform. T09 
induced robust cardiac expression of metabolic genes which are downstream of LXR-α, such as SREBP-
1c, ABCA1, and ABCG1. Together these results indicate that LXR exerts salutary effects in cardiac hy-
pertrophy, possibly via metabolic remodeling.
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INTRODUCTION
Chronic pressure overload leads to cardiac hypertrophy, which is a major risk factor for the develop-
ment of heart failure.1 Cardiac hypertrophic growth is associated with neurohormonal2 and metabolic3 
changes as well as with the activation of inflammatory signaling.4,5 Initially an adaptive mechanism, 
chronic pressure overload leads to cardiac hypertrophy, which later on can turn into cardiac failure. 
The reprogramming of gene expression underlying the development of left ventricular (LV) hyper-
trophy is highly complex.6 Several nuclear hormone receptors that act as transcription factors have 
been indicated in metabolic changes as well as in inflammatory pathways and may therefore serve as 
potential targets in the treatment of cardiac failure in response to cardiac hypertrophy.7,8 Liver X recep-
tors (LXRs) serve as ligand-activated transcription factors involved in metabolic pathways as well as in 
inflammatory responses.9 In addition, LXRs have also been reported as regulators of the renin–angio-
tensin–aldosterone system (RAAS) and of cell proliferation.10-12 There are two known isoforms of LXR: 
LXR-a (expressed mainly in liver, adipose tissue, macrophages, intestine, and spleen, but also in heart 
and kidney) and LXR-b (expressed ubiquitously).13 Although LXR-α expression has been identified in 
cardiac tissue, data on its role in cardiac responses to pathophysiological conditions remain scarce. 
In this study, we aimed to establish the role of LXRs in cardiomyocytes during the development of 
cardiac hypertrophy. Cultured cardiomyocytes with or without pro-hypertrophic stimuli were used to 
study the response to the synthetic LXR agonist T0901317 (T09). To corroborate our in vitro findings, 
an in vivo mouse model of cardiac pressure overload induced by aortic constriction (AC) was used.
METHODS
Culturing of cardiomyocytes
HL-1 cells (a gift from Dr. W.C. Claycomb, Louisiana State University Medical Center) were grown in 
Claycomb MediumTM (JRH Bioscience, Lenexa, KS, USA) supplemented with 10% foetal bovine serum 
(Invitrogen Corporation, Carlsbad, CA, USA), 0.1 mM norepinephrine, 2 mM L-glutamine (Invitrogen 
Corporation), and antibiotic/antimycotic solution (complete medium). All culture dishes and flasks 
were precoated with 0.5% fibronectin (BD Biosciences, Breda, The Netherlands) in 0.02% gelatin (Sig-
ma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). Cells were maintained in complete medium 
at 37°C in a humidified atmosphere of 95% air plus 5% CO
2
. At 70–80% cell confluence, the complete 
medium was replaced with serumand norepinephrine-free medium containing 0.5% BSA. Neonatal rat 
ventricular myocytes (NRVMs) were isolated from ventricles of 1–2 days old Sprague Dawley rats, as 
described previously.14 After 24 h serum starvation, cells were treated for 24 h with endothelin-1 (ET-1) 
(10 nM) with or without the LXR ligand agonist T09 (Cayman Chemicals, Ann Arbor, MI, USA). T09 was 
added to the cells 30 min prior to the ET-1 administration.
Staining of LXR-α and determination of cell size
After treatment, cells were washed three times with PBS and either used for RNA isolation (described 
below) or fixed in formaldehyde (4%). To visualize LXR-a expression, fixed cells were stained with a 
mouse anti-human LXR-α/NR1H3 monoclonal antibody (R&D Systems Europe, Abingdon, Oxford-
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shire, UK) followed by an Alexa Fluor-555 labelled goat anti-mouse antibody (Invitrogen Corporation; 
A21137) and visualized with fluorescent microscopy. 
To visualize sacromeric actin filament organization, fixed cells were stained with fluorescent rhoda-
mine phalloidin (Invitrogen Corporation) (1.5% in 1% BSA BPS) for 20 min at room temperature. There-
after, cells were counterstained with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). Image 
processing software (NIH Image J1.41/Windows; National Institutes of Health, Bethesda, MD, USA) 
was used to determine cell size (n=40). Cell surface area is depicted as a percentage of the surface 
area of control cells.
RNA interference
HL-1 cells were transfected with siRNA on the third day of plating (cell confluence at about 90%). Cells 
were transferred to 12-well plates and incubated for 8 h with 100 nM LXR-α: sense r(GAC AGA GCU 
UCG UCC ACA A) dTdT and antisense r(UUG UGG ACG AAG CUC UGU C) dGdG, LXR-β: sense r(GCC ACG 
UCA CCC ACU AUU A) dTdT and antisense r(UAA UAG UGG GUG ACG UGG C) dGdG (QIAGEN, Venlo, 
The Netherlands), or a silencer negative control small interference RNA of 19-base oligonucleotide de-
rived from a scrambled sequence in a 200 µL Opti-MEM (QIAGEN, Venlo, The Netherlands). Reduced 
serum medium (Invitrogen Corporation) and serum-free medium containing 2 µL LipofectamineTM 
2000 (Invitrogen Corporation) was used. After 48 h transfection, the siRNA–target cells were treated 
with ET-1, with or without T09 incubation. The isolated RNA was analysed by real-time PCR.
Animals and housing conditions
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Male C57Bl/6j wildtype 
mice were obtained from Harlan (The Netherlands) at the age of 9 weeks. LXR-α deficient (LXR-α-/-) 
mice on a C57Bl/6j background were generated by Deltagen, Inc. (Redwood City, CA, USA), as previ-
ously described.15 During the entire experiment, animals were kept on a 12 h light:12 h dark cycle with 
ad libitum access to food and water.
Surgical procedures
Mice (n=8) were fed either standard laboratory chow or chow supplemented with the synthetic LXR 
agonist T09 (50 mg/kg/day) throughout the entire experiment. Three days after the start of the diet in-
tervention, mice were anaesthetized using isoflurane (2% in O
2
). After opening the abdomen, the aor-
ta was constricted at the suprarenal level with an 8-0 nylon suture together with a blunted 29-gauge 
needle, which was pulled out thereafter. Sham operations were performed by isolation of the aorta 
without the ligation. Analgesic medication was administered subcutaneously, immediately after op-
eration (Temgesic; 0.05 mg/kg).
Echocardiographic and haemodynamic measurements and blood serum analysis
Four and 7 weeks after AC or sham operation, cardiac dimensions were measured using transthoracic 
echocardiography with a 14 MHz transducer (Vivid 7, GE Healthcare, Diegem, Belgium). Mice were 
anaesthetized as described above and body temperature was maintained by placing the mouse on a 
heating pad. Short-axis view and M-mode tracings were used to determine end-diastolic LV internal 
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diameter (LVIDd), posterior wall thickness (LVPWd), and interventricular septal thickness (IVSd). Left 
ventricular mass was calculated using the formula described by Troy et al.16; LVmass = 1.05 ([LVIDd + 
LVPWd + IVSd]3 - [LVIDd]3) gram. Mitral valve Doppler signals were used to measure E/A ratio. 
Heart rate (HR) and mean arterial pressure (MAP) were measured 7 weeks after AC or sham opera-
tion, using a Millar catheter (Mikro-tip 1.4F; SPR-839, Millar Instruments, Houston, TX, USA). Mice 
were anaesthetized as described above and a pressure transducer catheter was inserted into the right 
carotid artery. After the haemodynamic measurements, blood samples were taken and mice were 
sacrificed by excision of the heart. The atria and the right ventricle were removed and the remaining 
LV was snap-frozen for RNA analysis. Blood serum cholesterol levels were measured using Demecal 
Sets (LabAnywhere B.V., Haarlem, The Netherlands).
RNA analysis
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Total RNA from cells or tissues were extracted with TRIzol reagent (Invitrogen Corporation). cDNA syn-
thesis was performed using standard methods. Briefly, first-strand cDNA was prepared using random 
primer mix and thereafter used as a template for quantitative real-time reverse-transcriptase–PCR 
(qRT–PCR) (25 ng/reaction). mRNA levels are expressed in relative units based on a standard curve 
obtained by a calibrator cDNA mixture. All measured mRNA expression levels were corrected for 36B4 




All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Protein was isolated by homogenizing approximately 100 mg of frozen tissue in 1 ml radioimmuno-
precipitation-assay (RIPA) buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% 
Igepal ca-630 in 1xPBS) supplemented with protease inhibitor cocktail (Roche Diagnostics Corp., India-
napolis, IN, USA). After centrifugation at 14000 rpm for 20 minutes at 4°C, supernatant was collected 
and protein concentrations were determined using the DC assay (Bio-Rad, Veenendaal, The Nether-
lands) with a bovine albumin standard. SDS sample buffer was added to 20 μg of protein and samples 
were denaturized by heat at 99°C for 5 minutes.
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) (Thermo Scientific, 
Breda, The Netherlands), and transferred to PVDF membranes (Bio-Rad). Blots were incubated over-
night in anti-ATP-binding cassette G1 (ABCG1) polyclonal antibody (1:500, Novus Biologicals, Littleton, 
CO, USA), diluted in milk. To ensure equal amounts of protein were analysed on the blots, blots were 
also incubated in anti-α-tubulin (1:4000, Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands).
Statistical analysis
Results are expressed as mean+standard error of the mean. Statistical analysis was performed using a 
one-way analysis of variance (ANOVA) followed by post hoc omparisons (Tukey’s test) when the data 
were normally distributed. When the data were not normally distributed, we used a Kruskal–Wal-
lis H test, followed by individual comparisons of means (Mann–Whitney U test). All analyses were 
performed using SPSS (Version 16, SPPS Inc., Chicago, IL, USA). Values of P < 0.05 were considered 
statistically significant.
RESULTS
LXR activation inhibits ET-1 induced hypertrophy in cultured cardiomyocytes
Expression of LXR-α protein was assessed in HL-1 cells using a specific antibody targeted against LXR-α 
(figure 1A). To investigate if T09 could exert anti-hypertrophic effects on cardiomyocyte hypertrophy in 
vitro, we induced hypertrophy with ET-1 and measured atrial natriuretic peptide (ANP) mRNA expres-
sion and performed morphometric analysis.We used both HL-1 cardiomyocytes and NRVMs (except 
for the siRNA experiments which were only performed with HL-1 cells). Results were comparable in 
HL-1 cells and NRVM; only data obtained in HL-1 cells are shown. Treatment of HL-1 cardiomyocytes 
with T09 alone caused a sustained increase in sterol receptor element binding protein (SREBP)-1c 
mRNA (an established target gene of LXR17) after 12 h of incubation and a sustained decrease in ANP 
mRNA levels after 6 h of incubation (figure 1B). Based on these outcomes, the time point of 24 h T09 
incubation was chosen for further experiments. 
ET-1 treatment caused an increase in ANP mRNA expression (figure 1C). This increase was inhibit-
ed when cells were pre-treated with T09. Morphometric analysis revealed that the surface area of 
cells treated with ET-1 increased by 164% over that of control cells (figure 1D). The surface area of 
cells treated with T09 was increased by 122% over that of controls, significantly less compared with 
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ET-1 treatment alone (P < 0.05). Identical results were obtained in experiments with NRVM (data not 
shown). To address whether the inhibitory effect observed with T09 treatment is indeed conferred 
via LXRs, we employed siRNAs to knockdown LXR-α and LXR-β. HL-1 cells were transfected with ei-
ther scrambled siRNA or LXR-α/β siRNA. Transfection of cells with LXR-α/β siRNA resulted in a near 
complete knock-down of mRNA expression of LXR-α and LXR-β (data not shown). This inhibition of 
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LXR-α/β expression in HL-1 cardiomyocytes almost completely abolished the inhibitory effects of T09 
on cardiomyocyte hypertrophy evoked by ET-1 (figure 1E), implying that the inhibitory effect of T09 is 
a receptor-specific mechanism. Together these results indicate that LXR is involved in the hypertrophic 
response of HL-1 cells following ET-1 treatment and that activation of LXRs attenuates cardiomyocyte 
hypertrophy in vitro.
LXR activation attenuates cardiac hypertrophy in vivo following aortic constriction
To examine if the inhibitory effect of T09 on cardiomyocyte hypertrophy in vitro also holds true in vivo, 
wildtype and LXR-α-/- mice were subjected to AC and then treated with T09 or placebo. The experimen-
tal design of this study is shown in Figure 2. To confirm LXR activation following T09 treatment, liver 





 Wildtype mice L XR- -/- mice 
 sham AC AC+T09 sham AC AC+T09 
body weight (g) 28.4±0.7 27.0±0.5 24.9±0.7 30.7±1.2 32.3±0.9 30.5±1.0 
LV weight (mg) 160±6 195±3 * 161±9 † 133±4 200±5 * 213+12 * 
liver weight (mg) 1335±65 1405±43 2072±74 *† 1550± 1561±69 1711±60 *† 
LW/BW (mg/g) 47.0±1.7 52.0±1.4 83.3±1.0 *† 50.6±2.5 48.2±1.0 56.2±1.5 *† 
HR (bpm) 440±21 398±19 498±14 *† 420±16 399±20 406±14 
total cholesterol (mmol/l) 2.80±0.60 3.45±0.45 4.43±0.05 * 2.38±0.51 2.93±0.13 3.54±0.27 
HDL cholesterol (mmol/l) 0.80±0.06 0.90±0.10 1.30±0.07 * 0.76±0.12 0.88±0.11 1.40±0.09 * 
LDL cholesterol (mmol/l) 0.17±0.07 0.15±0.05 0.23±0.03 0.16±0.07 0.20±0.00 0.14±0.02 
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measured (table 1) after 7 weeks of AC. In wildtype mice, all these variables were increased following 
treatment with T09, indicative of LXR activation. In LXR-α-/- mice, T09 treatment increased LW/BW and 
HDL blood serum cholesterol levels to a lesser extent than in wildtype mice. These increases are prob-
ably attributable to activation of LXR-β. 
In wildtype and LXR-α-/- mice, total LV weight and LV weight normalized to body weight (LVW/BW) 
were increased following AC (table 1, figure 3A; P < 0.01 vs. sham). LXR activation by T09 treatment 
attenuated the increase in total LV weight in wildtype mice but not in LXR-α-/- mice, indicating that 
this effect is attributable to specific LXR-α activation. Cardiac B-type natriuretic peptide (BNP) mRNA 
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levels were measured using qRT–PCR. In wildtype and LXR-α-/- mice, cardiac BNP mRNA levels (figure 
3B) were increased following AC (P < 0.01). In wildtype mice, these increases were attenuated in mice 
treated with T09. In LXR-α-/- mice, T09 had no effect on cardiac BNP mRNA expression after AC. Using 
the data obtained by echocardiography, we calculated LV mass and outcomes were concordant with 
measured LV weights (Figure 3C). 
Echocardiography was performed 4 and 7 weeks after AC or the sham operation. Interventricular 
septum (IVS) (figure 4A and C) and left ventricular posterior wall thickness (LVPW) (figure 4B and D) 
were equal in sham-operated wildtype and LXR-α-/- mice, both after 4 and 7 weeks. After AC surgery, 
diastolic IVS and LVPW thicknesses were increased after 4 and 7 weeks, both in wildtype and LXR-α-/- 
mice. In wildtype mice, T09 treatment attenuated the increases in (diastolic and systolic) IVS and LVPW 
thickness 4 and 7 weeks after AC surgery (P < 0.05 vs. AC). In LXR-α-/- mice, no significant effect of T09 
treatment was found. Together, these results indicate that LXR activation attenuates cardiac hypertro-
phy following pressure overload.
LXR activation improves haemodynamic function following aortic constriction
To evaluate systolic and diastolic function, we used 2D/M-mode echocardiography and flow Doppler 
assessment of mitral inflow. Left ventricular diameters were not increased (data not shown) and con-
tractility (expressed as fractional shortening) was constant throughout the groups (figure 4C and F). 
Four and 7 weeks after AC surgery, no decrease in E/A ratio was found in wildtype mice or LXR-α-/- 
mice, indicating that although cardiac hypertrophy was present (as was established by an increase in 
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cardiac weight and an increase in cardiac wall thickening), no diastolic dysfunction had ensued (figure 
5A and B). Interestingly, treatment of wildtype mice with T09 caused a substantial increase in E/A ratio 
after 4 and 7 weeks of AC. The increase in E/A ratio is due to both an increase in the peak velocity of 
the E wave (indicating enhanced relaxation of the LV) and a decrease in peak velocity of the A wave 
(indicating decreased passive compliance; separate peak velocities not shown). This increase in E/A 
ratio following T09 treatment was found in wildtype mice, but not in LXR-a2/2 mice. 
A pressure transducer catheter was inserted into the right carotid artery to measure blood pressure. 
After 7 weeks of AC, there was an increase in MAP in wildtype and LXR-α-/- mice (figure 5C), this was 
due to an increase in systolic pressure rather than diastolic pressure (data not shown). In wildtype 
mice, the increase in blood pressure was blunted by T09, whereas in LXR-α-/-, T09 treatment had no 
effect on blood pressure.
LXR activation alters cardiac mRNA expression after aortic constriction
To uncover potential mechanisms for the observed beneficial effects of activation of LXR on cardiac 
hypertrophy, we measured several well-known downstream genes of LXR-α. T09 treatment caused 
a marked increase in ATP-binding cassette (ABC) subfamilies ABCG1 (figure 6A) and ABCA1 (figure 
6B) mRNA expression, as well as in SREBP-1c (figure 6C) mRNA expression (all: P < 0.01). This effect 
of T09 on ABCG1 and SREBP-1c mRNA was less pronounced in LXR-α-/- mice, although not absent 
(ABCG1; fivefold increase in wildtype mice and four-fold increase in LXR-α-/- mice, SREBP-1c; four-fold 
increase in wildtype mice and three-fold increase in LXR-α-/- mice; all AC vs. AC+T09, P < 0.01). In 
both wildtype and LXR-α-/- mice, AC surgery itself had no effect on 
the expression of ABCG1, ABCA1, and SREBP-1c mRNA. Protein 
expression of ABCG1, assessed by western blotting, corresponded 
with the increase in mRNA expression of ABCG1 found following 
T09 treatment in wildtype mice (see figure S1). In LXR-α-/- mice, 
T09 treatment showed no effect on ABCG1 protein levels. Expres-
sion of peroxisome proliferator activated receptor (PPAR)-α mRNA 
showed a trend towards a decrease following T09 treatment in 
wildtype mice (figure 6D) (P = NS). LXR-α mRNA expression was 
not altered after AC or T09 treatment in wildtype mice (figure 6E), 
neither was LXR-β mRNA expression (figure 6F). In LXR-α-/- mice, 
however, mRNA expression of LXR-β was increased following AC.
DISCUSSION
This study demonstrates that the activation of LXRs attenuates cardiac hypertrophy. Using an in vitro 
model of cultured cardiomyocytes, we show that LXR activation attenuates cardiomyocyte size and 
cardiomyocyte expression of ANP, a marker gene for the onset of cardiac hypertrophy. In addition, we 
show in an in vivo model of cardiac hypertrophy that LXR activation decreases cardiac hypertrophy 
along with hypertension and improves diastolic parameters. These effects were substantially blunted 
in LXR-α-/- mice, indicating that these are LXR-α- dependent effects. 
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So far, only a few studies have specifically investigated the role of LXRs in cardiovascular function. Most 
published data have suggested that LXRs may be promising novel targets in cardiovascular disease 
through their effects on lipid metabolism and atherosclerosis.18 Very recently, however, Wu et al.19 
reported that LXR activation in cultured rat cardiomyocytes reduces hypertrophy in response to an-
giotensin II treatment. Here we confirm and extend these results using the murine atrial cell line HL-1 
and NRVMs. We provide further proof that this is indeed a LXR-dependent effect. We employed siRNA 
interference, which causes knock-down of LXR expression, and showed that the attenuating effect of 
T09 is absent in this condition. 
To corroborate these in vitro findings in vivo, we employed a mouse model to test the effects of LXR 
activation on myocardial hypertrophy. With this model, the possibility that LXR only counter-regulates 
specific pro-hypertrophic stimuli (like ET-1 or AngII) is tested by using the ‘unspecific’ model of pres-
sure overload, which induces a rather general hypertrophic response. Here we show that also in this 
model, T09 exerts anti-hypertrophic effects. In their studies, Wu et al.19 report an increase of LXR-α 
mRNA and protein expression following 14 days of AC in wildtype mice and more pronounced hyper-
trophy markers in LXR-α-/- mice compared with wildtype mice. We did not confirm this increase in 
LXR-α expression in our study. We treated (wildtype and LXR-α-/-) with T09 to activate LXRs in pressure 
overload. We report here that activation of LXRs with T09 blunts the hypertrophic response in vivo, 
which was assessed by LV weight, echocardiography, and BNP expression, which were all reduced by 
T09 treatment. However, this effect was not observed in LXR-α-/- mice, which supports the notion that 
the effect is brought about by activation of LXR-α, and conferred via downstream effects. This obser-
vation is in line with Wu et al.19 who observed that cardiac hypertrophy following AC was more pro-
nounced in LXR-α-/- mice. We could not confirm the increased susceptibility of these mice to pressure 
overload - using echocardiography, we assessed cardiac hypertrophy and diameters 4 and 7 weeks 
after AC surgery and observed no significant differences in wall thickening or E/A ratios between wild-
type and LXR-α-/- mice. This discrepancy may be explained by the different time points chosen (14 days 
vs. 4 weeks and 7 weeks). 
In addition to a decrease in LV hypertrophy after AC surgery, we observed a decrease in blood pres-
sure following treatment of wildtype mice with T09. Abdominal AC is associated with hypertension, 
possibly due to hypoperfusion of the kidneys and an activated RAAS.20 LXR has been identified as a 
regulator of renin transcription in vitro and in vivo.10 We have previously reported an inhibitory effect 
of LXR activation on isoproterenol-induced renin transcription, together with decreased renal and 
cardiac expression of angiotensin converting enzyme (ACE) mRNA.21 Data on the functional effects 
of the interaction between LXR activation and the RAAS have hitherto remained scarce. Leik et al.22 
reported that LXR activation reduces acute angiotensin II (AngII)-mediated pressor responses in rats. 
They measured blood pressure immediately following AngII infusions after the rats had been treated 
with a synthetic LXR agonist for 7–15 days. To our knowledge, the present study is the first to report 
the long-term effects of LXR activation on blood pressure in a model in which hypertension is induced 
in vivo. This observation clearly warrants further study. 
It has been observed in clinical studies that changes in LV hypertrophy may not be exclusively explained 
by the blood pressure lowering effect of a drug.23 In addition to the blood pressure lowering effect, 
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direct LXR activation in the myocardium may also explain the observed changes in LV hypertrophy. 
Several in vitro studies have described anti-proliferative effects of LXR activation in various cell types, 
including VSMCs,24 pancreatic islet β cells,25 keratinocytes,26 and breast cancer cells.27 Our study dem-
onstrates that LXR activation also inhibits cardiomyocyte hypertrophy. Of note, adult cardiomyocytes 
respond to stress with hypertrophy rather than proliferation, so that the proposed anti-proliferative 
mechanisms in previous studies, such as interference in the cell cycle24 or apoptosis,25 may not be op-
erative in cardiomyocytes. The precise mechanisms in the heart are still unknown. Wu et al.19 recently 
suggested that NF-kB may confer the antihypertrophic effects of LXR-α in cardiomyocytes. The NF-κB 
complex is involved in cardiac remodeling and disruption of this transcription factor in genetically engi-
neered mice produced attenuation of cardiac remodeling following AngII- and isoproterenol-induced 
hypertrophy and after myocardial infarction.28,29 However, other cardiac transcription factors such as 
Sp130 or other kinases such as MAPK31 may be controlled by LXRs as well and thus be involved in re-
modeling pathways of the hypertrophic heart. We show here that like in other tissues or cell types,17 
the transcription factor SREBP-1c is increased in the hearts of mice treated with T09. SREBP-1c has 
been shown to be involved in parasympathetic responses in the murine heart,32 however its role in the 
development of cardiac remodeling remains to be elucidated. In addition, we also show an increase 
in mRNA expression of other specific target genes of LXR, e.g. ABCA1 and ABCG1, combined with an 
increase in protein levels of ABCG1. These changes in specific LXR target genes show increased activity 
in the myocardium of LXR as a transcription factor. Together with the activation of systemic LXR targets 
(as shown by serum cholesterol increases), these data strongly support the notion that LXR specific 
pathways are activated by T09 treatment, both systemically and locally (in the myocardium). 
In conclusion, our results show that the activation of LXRs attenuates hypertrophy in vitro and in vivo. 
We therefore postulate that LXRs can be regarded as potential targets for novel therapeutic interven-
tions in cardiovascular disease, especially LV hypertrophy and hypertension.
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Statins (HMG-CoA reductase inhibitors) are well known for their cholesterol-lowering effects. Experi-
mental studies have shown that statins also reduce the development of left ventricular hypertrophy 
(LVH). To study how these cholesterol lowering drugs are capable of reducing LVH, we induced LVH 
in mice that are liver X receptor-α (LXR) deficient (LXR-α-/- mice) and treated them with statins. LXR 
is a nuclear receptor that plays a crucial role in the regulation of cholesterol metabolism, but its role 
in the cholesterol-lowering effects of statins is yet to be defined. LVH was induced in wildtype and 
LXR-α-/- mice, using abdominal aortic constriction (AC). In both wildtype and LXR-α-/- mice, AC caused 
significant LVH as was measured by wall thickening, increased LV weight, and increased levels of car-
diac BNP mRNA expression. Also, MAP was increased in both wildtype and LXR-α-/- mice after AC. In 
wildtype mice, all these variables were reduced when mice were treated with pravastatin (50 mg/kg/
day). In LXR-α-/- mice however, pravastatin appeared to have no effect on these variables. All results 
were present 4 weeks after AC and more pronounced 7 weeks after AC. This study shows that although 
statin treatment attenuates LVH in wildtype mice, LVH development in LXR-α-/- mice is not affected by 






Left ventricular hypertrophy (LVH) is the structural remodeling of the left ventricle as a response to 
long-lasting haemodynamic overload. Despite its adaptive nature, LVH is associated with an increased 
risk of cardiovascular morbidity and mortality1 and the prevention or regression of LVH is considered 
to be of high therapeutic importance. Recently we showed that activation of liver X receptors (LXRs) 
leads to attenuation of LVH in a mouse model of cardiac pressure overload.2 LXRs are well known for 
their important role in cholesterol metabolism3 but are also involved in inflammatory responses,4 cell 
proliferation5 and serve as regulators of the renin-angiotensin-aldosterone system (RAAS).6 There are 
two known isoforms of LXR: LXR-α (expressed mainly in liver, adipose tissue, macrophages, intestine, 
and spleen, but also in heart and kidney) and LXR-β (expressed ubiquitously).7 Although LXR-α is ex-
pressed in cardiac tissue, its role in cardiac responses to pathophysiological conditions remains largely 
unclear.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) are known 
for their plasma cholesterol lowering capacity.8 Lowering serum lipid levels leads to regression or sta-
bilization of atherosclerotique plaques, which may cause the reduced morbidity and mortality seen 
in patients with coronary artery disease treated with statins. Additional clinical evidence shows that 
statins also excert beneficial effects independent of diminished plasma lipid levels, likely caused by 
various effects statins have on a cellular or subcellular level or indirectly by lowering cholesterol ac-
cumulation in tissues.9 These ‘pleiotropic’ effects include attenuation of the pathological remodeling 
of the heart and vessels, e.g. regression of LVH.10 
Recent studies have shown an interaction between the molecular pathways activated by LXRs and the 
effects of statin treatment.11,12,13 We therefore hypothesize that the attenuation of LVH by statin treat-
ment is mediated by LXR activation. To test this hypothesis, we tested how mice deficient for the LXR-α 
isotype (LXR-α-/- mice) respond to statin treatment in a model of cardiac pressure overload.
METHODS
Animals and housing conditions
All experiments were approved by the local Committee on Animal Experimentation and were per-
formed under international guidelines on animal experimentation. Male C57Bl/6j WT mice were ob-
tained from Harlan (Netherlands) at the age of 9 weeks. LXR-α deficient (LXR-α-/-) mice on a C57Bl/6j 
background were generated by Deltagen, Inc (Redwood City, CA, USA), as previously described.15 Dur-
ing the entire experiment, animals were kept on a 12 hour light:12 hour dark cycle with ad libitum 
access to food and water.
Surgical procedures
Mice (n=8) were fed either standard laboratory chow or chow supplemented with pravastatin (Sigma-
Aldrich Chemie B.V., Zwijndrecht, The Netherlands) (50 mg/kg/day) throughout the entire experiment. 
3 days after the start of the diet intervention, mice were anesthetized using isoflurane (2% in O
2
). 
After opening the abdomen, the aorta was constricted at the suprarenal level with an 8-0 nylon suture 
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together with a blunted 29-gauge needle, which was pulled out thereafter. Sham operations were 
performed by isolation of the aorta without the ligation. Analgesic medication was administered sub-
cutaneously, immediately after operation (Temgesic; 0.1 mg/kg).
Echocardiographic and haemodynamic measurements and blood serum analysis
4 and 7 weeks after AC or sham operation cardiac dimensions were measured using transthoracic 
echocardiography with a 14 MHz transducer (Vivid 7, GE Healthcare, Diegem, Belgium). Mice were 
anesthetized as described above and body temperature was maintained by placing the mouse on a 
heating pad. Short-axis view and M-mode tracings were used to determine end-diastolic LV internal 
diameter (LVIDd), posterior wall thickness (LVPWd), and interventricular septal thickness (IVSd). Mitral 
valve Doppler signals were used to establish E/A ratio. 
Heart rate (HR) and mean arterial pressure (MAP) were measured 7 weeks after AC or sham operation, 
using a Millar catheter (Mikro-tip 1.4F; SPR-839, Millar Instruments, Houston, TX, USA). Mice were 
anesthetized as described above and the right carotid artery was inserted with the pressure trans-
ducer catheter. After the haemodynamic measurements, mice were sacrificed by excision of the heart. 
Atria and the right ventricle were removed and the remaining LV was snap-frozen for RNA analysis. 
Whole blood samples were taken and analyzed using the Demecal Lifestyle SetTM (LabAnywhere b.v., 
Haarlem, The Netherlands) to measure serum levels of cholesterol and tryglicerides.
RNA analysis
All disposable products were purchased from Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands. 
Total RNA from cells or tissues was extracted with TRIzol reagent (Invitrogen Corporation, Carlsbad, 
CA, USA). cDNA synthesis was performed using standard methods. Briefly, first strand cDNA was pre-
pared using random primer mix and thereafter used as a template for quantitative real-time Reverse-
Transcriptase PCR (qRT-PCR) (50 ng/reaction). mRNA levels are expressed in relative units based on 
a standard curve obtained by a calibrator cDNA mixture. All measured mRNA expression levels were 
corrected for 36B4 reference gene expression. Primers used for analysis are listed in table 1. 
Statistical analysis
Results are expressed as mean+standard error of the mean. Statistical analysis was performed using a 















were normally distributed. When the data were not normally distributed, we used a Kruskal–Wal-
lis H test, followed by individual comparisons of means (Mann–Whitney U test). All analyses were 
performed using SPSS (Version 16, SPPS Inc., Chicago, IL, USA). Values of P < 0.05 were considered 
statistically significant.
RESULTS
Pravastatin attenuates LVH in wildtype but not in LXR-α-/- mice
To assess LVH 7 weeks after AC, left ventricles were weighed (table 2). In wildtype mice and in LXR-α-/-, 
AC caused an increased left ventricular weight compared to sham operated mice. In wildtype mice, 
this increase was attenuated when mice were treated with pravastatin. In LXR-α-/- mice however, no 
effect was seen on left ventricular weight in AC mice treated with pravastatin compared to AC mice on 
standard control chow. Figure 1A shows the left ventricular weight as a ratio of the total body weight. 
Correction for body weight shows the same results as the left ventricular weights alone; in wildtype 
mice treatment with pravastatin attenuates LVH, but in LXR-α-/- mice no effect of pravastatin was found 
compared to AC mice fed with normal standard chow. Total cholesterol, LDL cholesterol, 
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HDL cholesterol, and triglyceride levels in blood serum were not affected by AC and/or treatment with 
pravastatin (table 2). 
Analysis of cardiac mRNA expression shows that transcription of B-type natriuretic peptide (BNP) is 
increased 7 weeks after AC in both wildtype and LXR-α-/- mice (figure 1B). In wildtype mice this in-




mice however, the pravastatin treatment seemed to have no effect on cardiac BNP mRNA levels. 
Similar effects were found on mean arterial blood pressure (MAP) (figure 1C). In mice subjected to AC 
MAP increased compared to sham operated animals in both wildtype and LXR-α-/- mice. Pravastatin 
treatment attenuated this hypertension in wildtype mice, but not in LXR-α-/- mice.
Echocardiographic measurements were performed 4 and 7 weeks after AC to assess cardiac dimen-
sions. 4 weeks after AC, wildtype mice showed increased IVSd and LVPWd compared to sham operated 
mice. Both IVSd and LVPWd were attenuated when AC wildtype mice were treated with pravastatin. 
In LXR-α-/- mice however, only IVSd was increased after 4 weeks AC while LVPWd remained unaltered. 
At this 4 week time point, AC LXR-α-/- mice treated with pravastatin showed less thickening of the IVSd 
than their control AC mice.
7 weeks after AC, wildtype mice showed similar, but more pronounced results as after 4 weeks AC. 
Both IVSd and LVPWd were increased in AC mice and were attenuated when mice were treated with 
pravastatin. In LXR-α-/- mice however, IVSd and LVPWd were also increased 7 weeks after AC, but treat-
ment with pravastatin had no effect on the wall thickening in these area’s. Other variables measured 
by echocardiography at 4 and 7 weeks after AC are listed in table 3.
Pravastatin alters gene expression of LXR-α target genes
To gain insight in the molecular processes underlying the interplay of pravastatin and LXR, we mea-
sured cardiac mRNA expression of several LXR-α specific target genes (figure 3). At baseline, expres-
sion of sterol receptor element binding protein type 1c (SREBP-1c), peroxisome proliferator activated 
receptor (PPAR)-γ and ATP-binding cassette type A1 (ABCA1) is higher in wildtype mice compared 
to LXR-α deficient mice (figure 3A-C). Treatment with pravastatin decreased the expression of these 
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LXR-α target genes in wildtype mice, whereas the expression in LXR-α-/- mice remained unaltered. Ex-
pression of ABCG1, also a known LXR-α target gene, remained unchanged after AC or statin treatment 
in both wildtype and LXR-α-/- mice.
DISCUSSION
Previously, we and others showed that activation of LXRs by a synthetic agonist attenuates the de-
velopment of LVH.2,14 In this study we confirm that in a model of pressure overload, treatment with 
pravastatin attenuates LVH in wildtype mice. In addition, we show that these anti-hypertrophic effects 
are abolished in LXR-α-/- mice. Together, these results suggest an important role for LXRs in the path-
way through which statins are able to attenuate the development of LVH. 
A wide body of evidence supports the notion that statins attenuate LVH as a pleiotropic effect of these 
drugs (reviewed in15). However, it remains unclear through which precice mechanisms these effects 
are exerted. Our data (as well as earlier publications16) show that in wildtype mice, statin treatment 
results in lowered MAP. This suggests that the attenuation of LVH in these mice might be exerted by 
the blood pressure lowering effects of statins. In LXR-α-/- mice statins did not affect the MAP, showing a 
crucial role for LXRs in the blood pressure lowering effects of statins. Indeed, earlier studies show that 
activation of LXRs results in blunted activation of the RAAS and decreased blood pressure.6,17 
It has been observed in clinical studies however, that changes in LVH may not be exclusively explained 
by the blood pressure lowering effect of a drug.18 Previously we showed that in vitro (so without any 
systemic haemodynamic effects), LXR activation results in attenuation of cardiomyocyte hypertrophy.2 
In addition we show here that statin treatment directly affects cardiac mRNA expression of several 
target genes of LXR. So on top of its blood pressure lowering effects, statins also directly affect gene 
transcription in cardiomyocytes. LXR-α dependency in this mechanism is again confirmed by the ab-
sence of these effects in hearts of LXR-α-/- mice.
Also in human macrophages, statins have been shown to decrease the expression of ABCA1 and 
ABCG1, specific target genes for LXR.11 The authors speculate that this decreased expression of LXR 
target genes is attributable to a decreased availability of oxysterol ligands for LXR, caused by decreased 
24(S),25-epoxycholesterol synthesis from the mevalonate pathway which is inhibited by statins. The 
current study confirms these findings; we also found that the LXR target genes SREBP-1c and ABCA1 
were downregulated in hearts of statin treated mice. 
The notion that statins decrease the availability of oxysterol ligands for LXR seems in contrast with car-
dioprotective role of LXRs. This apparent discrepancy can be explained by the hypothesis that statins 
exert their anti hypertrophic effects through the inhibition of SREBP-2 transcription. Like SREBP-1c, 
SREBP-2 is a transcription factor that stimulates the expression of specific target genes.19 While SREBP-
1c is involved in lipogenesis, SREBP-2 stimulates cholesterol synthesis and is activated in response to 
cholesterol depletion. Target genes of SREBP-2 include HMG-CoA synthase and reductase, which are 
both higher expressed in livers of LXR-α-/- mice compared to wild type mice (data not shown).  LXR-α-/- 
mice are characterized by a higher expression of SREBP-2.3 Inhibition of SREBP-2 transcription by 




and how SREBP-2 is involved in the hypertrophic response of the heart, but it could be suggested that 
SREBP-2 targets hypertrophic genes. Additional studies are warranted to test this hypothesis.
Baba et al. show that there is a negative correlation between blood cellular LXR-α mRNA expres-
sion and the severity of coronary heart disease.20 Also, patients treated orally with atorvastatin show 
increased mRNA expression of LXR-α in their blood mononuclear cells, whereas PPAR-α and PPAR-γ 
mRNA expressions are decreased. It is suggested that the increase in LXR-α expression serves as a pro-
tective mechanism against the development of coronary atherosclerosis. Although our study confirms 
the decrease in PPAR-γ mRNA found after statin treatment, we did not see an increase in cardiac LXR-α 
mRNA expression (data not shown). However, it is not unlikely that the response of cardiomyocytes to 
statin differs from the response of blood mononuclear cells with respect to LXR-α mRNA expression. 
An increase in LXR-α expression in blood mononuclear cells (e.g. macrophages) might explain why 
statins exert a cardioprotective effect in the wildtype mice, but not in LXR-α-/- mice. 
In conclusion, we show in this study that LXR-α plays a crucial role in the anti-hypertrophic effects on 
the heart by statins. These findings confirm the suggested interplay of LXRs and statins and further 
support a protective role for LXR-α in the development of LVH.
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Liver X receptors (LXRs) play a crucial role in lipid and cholesterol metabolism, but can also act as a 
modulator of the cardiovascular system. We hypothesized that LXR activation reduces adverse cardiac 
remodeling after a myocardial infarction. Male C57Bl/6j mice were subjected to myocardial infarction 
(MI) by permanent ligation of the left anterior descending coronary artery. Three experimental groups 
were studied; sham, MI, and MI treated with the synthetic LXR agonist T0901317 (T09). After 3 weeks, 
myocardial function was assessed and animals were sacrificed hereafter. Ejection fraction, fractional 
shortening and hypertrophic responses of the myocardium were significantly affected in MI mice com-
pared to MI-sham mice. In MI-T09 mice, ejection fraction and fractional shortening were improved 
and hypertrophic responses were attenuated compared to MI mice. In conclusion, LXR activation im-
proves cardiac function after MI, confirming a cardio-protective role for LXR.
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INTRODUCTION
Cardiac (or ventricular) remodeling is the common term used for pathophysiological changes in size, 
shape, and function of the heart after cardiac injury.1 Remodeling may occur after myocardial infarc-
tion, but also in response to chronic pressure overload (aortic stenosis, hypertension), volume over-
load (valvular regurgitation), inflammatory heart muscle disease (myocarditis), congenital heart dis-
ease (intracardiac shunting) or genetic cardiomyopathy. The initial remodeling response after cardiac 
injury is considered beneficial and is aimed to cope with the increased loading and work load of the 
heart. The cellular re-arrangement of the ventricular wall and activated neurohormonal systems re-
sults with maintained (or improved) cardiac output. However, the very adapative mechanisms that 
are initially beneficial become adverse on the long term and progressive remodeling occurs, which 
ultimately may lead to heart failure. The time course and the extent of remodeling are influenced by 
many factors, such as the severity of the insult, secondary events (recurrent ischemia or infarction), 
neurohormonal activation, hemodynamic load, and genetic factors.
The nuclear hormone receptor LXR plays a central role in reverse cholesterol metabolism, which stim-
ulates cholesterol efflux from tissues.2 Endogenous ligands of LXRs are oxidized cholesterol particles 
(oxysterols); intermediate metabolites of cholesterol.3 Activation of LXRs initiates the transcription of 
downstream genes, which stimulate the cholesterol efflux. Therefore LXR has been proposed as a po-
tential target in the treatment of atherosclerosis. Recently, it has been shown that the liver X receptor 
(LXR)-α attenuates cardiac remodeling in models of pressure overload.4,5
Aside from their central role in cholesterol metabolism, LXRs modulate many other pathways of the 
cardiovascular system. It has been shown that LXR activation leads to decreased activity of the renin-
angiotensin-aldosterone system (RAAS).6,7 In addition, increased LXR activity leads to diminished in-
flammatory responses.8 Macrophages are known to be critically involved in the inflammatory respons-
es after MI.9 Interestingly, macrophages, which express LXR abundantly, show altered inflammatory 
responses when treated with LXR agonists.10 Myocardial infarction (MI) remains to be the main reason 
for left ventricular (LV) dysfunction in a clinical setting. This post-MI remodeling is highly influenced by 
inflammatory responses.11
In summary, LXRs have been shown to play a protective role in the cardiovascular system. In addition, 
they are capable of attenuating inflammatory responses. Therefore, we hypothesize that LXR activa-
tion would reduce adverse cardiac remodeling after MI. 
METHODS
Animals and housing conditions
All experiments were approved by the local Committee on Animal Experimentation and were per-
formed under international guidelines on animal experimentation. Male C57Bl/6j WT mice were ob-
tained from Harlan (Netherlands) at the age of 9 weeks. During the entire experiment, animals were 
kept on a 12 hour light:12 hour dark cycle with ad libitum access to food and water.
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Induction of MI 
Mice (n=6-8) were anesthetized with isoflurane, and intubated using a 20-gauge intravenous cath-
eter with a blunt end. Mice were artificially ventilated at a rate of 150 strokes/min, using a rodent 
ventilator (Harvard Apparatus Rodent Ventilator Model 845) with isoflurane (2% in O2). The thorax 
was opened in the third intercostal space and the left anterior descending (LAD) coronary artery in 
mice was permanently ligated with a 6-0 non-absorbable prolene suture above the branching of the 
LAD. Sham-operated controls underwent the same procedure, except for induction of MI. Immediately 
after the surgical procedures, mice were fed either standard laboratory chow or chow supplemented 
with the synthetic LXR agonist T09 (50 mg/kg/day) throughout the entire experiment. This dose was 
previously shown to cause a strong, sustained activation of LXRs in vivo.12
Echocardiographic measurements
Three weeks after MI or sham operation cardiac dimensions were measured using transthoracic echo-
cardiography with a 14 MHz transducer (Vivid 7, GE Healthcare, Diegem, Belgium). Mice were anes-
thetized as described above and body temperature was maintained by placing the mouse on a heating 
pad. Short-axis view and M-mode tracings were used to determine end-diastolic LV internal diameter 
(LVIDd), posterior wall thickness (LVPWd), and interventricular septal thickness (IVSd). From M-mode 
tracings fractional shortening and ejection fraction (Teichholz’s formula) were calculated. Mitral valve 
Doppler signals were used to establish heart rate (HR) and left ventricular cardiac output (LVCO), from 
which the stroke volume was calculated.
Statistical analysis
Measured values are presented as means ± standard error of the mean (SEM), unless stated other-
wise. Statistical analysis was performed using an analysis of variance (ANOVA) with post hoc compari-
sons (Tukey’s test). A p-value of <0.05 was considered statistically significant.
RESULTS
LXR activation attenuates MI-induced cardiac hypertrophy
Three weeks after MI, mice were sacrificed and the LV and liver were weighed. The T09 treatment 
caused a significant increase in liver weights in the MI+T09 group (table 1). This is caused by accumula-
tion of triglycerides in the liver; a known side effect of LXR agonism.13 These data confirm that the T09 
diet stimulated LXR activation.





sham MI MI + T09
body weight (g) 30.0±0.8 28.5±0.5 26.9±1.5
LV weight (mg) 142±7 179±5 * 155±13
Liver weight (mg) 1310±55 1227±163 2077±124 *†
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However, LXR activation by T09 treatment attenuated the increase of LV weight after MI. The mean LV 
weight of the MI+T09 mice was still higher than that of sham-operated mice, but the difference did not 
reach statistical significance (p=0.53).
LV dimensions, assessed by echocardiography were increased after MI due to cardiac dilation (table 
2): diastolic and especially systolic LV internal diameters were dramatically increased. Treatment with 
T09 attenuated the increase of the LV diameters. Wall thickness of the anteroseptal wall (IVS) was sub-
stantially thinner in MI mice, due to scarring. Posterior wall was not hypertrophied, possibly because 
of the increased wall stress due to the LV dilatation. Posterior wall thickness was actually significantly 
thinner in MI mice, whereas treatment with T09 resulted in a posterior wall thickness equal to sham 
operated mice. 
Together, these data suggest that activation of LXRs results in attenuated cardiac hypertrophy after a 
MI.
LXR activation improves cardiac function after a MI
From the cardiac dimensions assessed by echocardiography, the fractional shortening (FS) was cal-
culated. MI caused a dramatic decrease in FS, but this was improved when animals were treated 
with T09 (figure A). This is reflected in the calculated LV ejection fraction; MI caused a decrease in LV 
ejection fraction compared to sham-operated mice, but treatment with T09 attenuated this decrease 
significantly (figure B). Stroke volume, calculated from the HR and LVCO, was not altered by LXR activa-




In this pilot study we show that activation of LXR results in attenuated cardiac hypertrophy after a MI. 
This was demonstrated by the attenuation of LV hypertrophy and LV dilatation observed in T09-treated 
mice compared to the MI mice without T09 treatment. Also, the decrease in wall thickening after MI 
was attenuated in MI+T09 mice compared to MI mice. In addition, it is suggested that the attenuated 
cardiac hypertrophy and remodeling by LXR activation results in preserved cardiac function. Fractional 
shortening and ejection fraction were higher in MI+T09 mice compared to MI mice. These data sug-
gest a cardio-protective role for LXR.
This is the first study focused on the role of LXR in cardiac remodeling post-MI. A few other nuclear 
hormone receptors have been shown to also exert a protective role in the heart post-MI. Activation 
of PPAR-α and PPAR-γ reduced MI size and improved contractile dysfunction caused by ischemia/
reperfusion injury in rat models of cardiac failure14,15 and blocking the mineralocorticoid receptor has 
been shown to improve LV function in experimental studies16 and to reduce morbidity and mortality in 
patients with MI.17 In addition to these studies, we now propose LXR as a new target in the treatment 
of cardiac remodeling after MI.
In this pilot study, we did not perform additional tissue analyses that would provide mechanistic clues 
how LXR exerts its cardio-protective effects. It seems plausible that LXR attenuates the complicated 
process of post-MI cardiac remodeling via various pathways, as LXR influences so many (pleiotropic) 
processes. Recent studies form our group and others have reported the cardio-protective role of LXR 
in the process of cardiac remodeling in pressure overload models. This was associated with decreases 
in blood pressure, cardiomyocyte hypertrophy2 and inhibition of the NK-kB pathway.3 Because LXR 
plays a crucial role in cholesterol and lipid metabolism, most studies have focused on its ability to 
prevent atherosclerosis.18 LXRs are however also able to influence the cardiovascular system via other 
means than by cholesterol and lipid metabolism. Direct actions on cardiomyocytes2, macrophages9, 
and the RAAS5,6 enable LXRs to influence cardiac remodeling, inflammatory responses and blood pres-
sure homeostasis. Because all these processes are critically involved in the process of cardiac remod-
eling post-MI, further research is warranted to establish through which mechanism(s) LXR influences 
this process. 
In conclusion, this pilot study showed that activation of LXR attenuates adverse cardiac remodeling 
post-MI and improves cardiac function post-MI. The pathways through which LXRs exert these effects 
are yet to be elucidated. These results provide further proof for a potential role for LXR activating 
drugs with the aim to prevent cardiac remodeling. 
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Nuclear hormone receptors (NHRs) control fatty acid, lipid, and carbohydrate metabolism. Recently, 
NHRs have also been implicated in cell differentiation, proliferation, and inflammation. As these pro-
cesses are all involved in the pathophysiology of cardiovascular disease, pharmacological targeting 
of NHRs is a promising strategy in its prevention and treatment. Although many experimental stud-
ies have explored the effects of NHRs on vascular and cardiac remodeling, the potential interplay of 
NHRs with other established regulatory systems of the cardiovascular system has not been elucidated. 
Given the pivotal role of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular disease, 
we reviewed the currently available evidence supporting the hypothesis that NHRs are involved in 
RAAS regulation. We describe and discuss data implying that pharmacological or non-pharmacological 
modulation of NHRs might have ancillary effects on RAAS activity that we need to take into account.
81
NHRS AS REGULATORS OF THE RAAS
6
INTRODUCTION
The renin-angiotensin-aldosterone system (RAAS) has been identified as the main system involved in 
blood pressure regulation, renal hemodynamics, and sodiumvolume homeostasis. Furthermore, the 
RAAS directly affects vascular and cardiac remodeling through proliferative and inflammatory signal-
ing. Pharmacological targeting of the RAAS is a consolidated and evidence-based approach in the 
treatment of various aspects of cardiovascular disease. An exploding number of recent studies have 
provided novel insights into nuclear receptor biology in relation to cardiovascular (patho)physiology. 
In particular, members of the nuclear hormone receptor (NHR) superfamily have been identified as 
key molecules in various relevant cellular processes. As such, NHRs have been proposed as amenable 
targets for therapy, and their role in cardiovascular disease is currently explored.
This review focuses on the potential effects of NHRs on the RAAS, summarizing the extensive body 
of evidence from experimental, animal, and clinical studies, suggesting that NHRs and the RAAS are 
closely intertwined. We discuss how these findings might translate into the clinical setting and discuss 
the (older) trials that evaluated NHR agonists in humans. We postulate that therapies targeting NHRs 
will cause ancillary effects (ie, modulating the RAAS) that need to be considered.
NHRS AND THE RAAS
NHRs constitute a superfamily of ligand-activated transcription factors involved in multiple cellular 
functions, acting as monomers, homodimers, or heterodimers (usually with the retinoid X receptors). 
The NHR superfamily is divided into 6 subfamilies (table S1).1 Cloning of the NHRs revealed that many 
of the NHRs share close homology. The fourth, fifth, and sixth classes (not mentioned in table S1) 
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include various NHRs that are less well described. NHR ligands include hormones, xenobiotics, prosta-
glandins, fatty acids, and cholesterol derivatives. An overwhelming amount of evidence exists for the 
role of NHR in cholesterol, lipid, and glucose metabolism.2 Several NHRs are provisionally indicated as 
“orphan” receptors, because their ligands are as yet unknown. After activation by their ligands, NHRs 
bind to DNA-responsive elements located within target gene promoters or have cross-talk with other 
signaling pathways. Effects are often modified by nuclear coregulators (coactivators and corepressors).
However, if and how different NHRs may affect the RAAS remain largely unknown. Angiotensin II (Ang 
II) is the main effector peptide of the RAAS. Other end products are generated as well, such as angio-
tensin IV, angiotensin (1-7), and others (detailed in Figure S1). In this review, we focus mainly on the 
effects of NHRs on renin, angiotensinogen, and angiotensin receptors.
NHRS AND RENIN
Renin is (almost) exclusively secreted from specialized juxtaglomerular (JG) cells, located in the affer-
ent arterioles of the kidney. Renin transcription is tightly regulated.3 It has become clear that several 
NHRs regulate renin transcription through interaction with specific responsive elements in the renin 
promoter (figure 1). Through specific responsive elements, NHRs can act as either positive or negative 
regulators of renin transcription (table 1).
Liver X receptors
Liver X receptor (LXR)-α and the highly homologous LXR-β are important modulators of lipid and glu-
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gut, heart, kidney, and adrenals, whereas LXR-β is ubiquitously expressed. Tamura et al.5 provided 
evidence that LXRs play an important role in renin regulation. Previously, they described a specific 
responsive element in the mouse renin promoter, called cAMP-negative response element (CNRE; 
figure 1). LXR-α was identified as a CNRE-binding protein that regulates renin mRNA expression. This 
finding was confirmed recently using a mouse in vivo model.6 Both LXR-α and LXR-β were shown to 
be regulators of renin transcription. Renal expression of LXR-α was found confined to JG cells (figure 
2). Interestingly, LXR-α and LXR-β markedly differ in their control of renin transcription, because the 
latter constitutively upregulates renin mRNA expression, whereas LXR-α increases renin mRNA only 
in a cAMP-dependent manner. Importantly, high-renin status models were associated with prominent 
LXR-α binding activity to the CNRE. Experiments in LXR-deficient mice confirmed that LXR-α is neces-
sary for the cAMP-dependent response of JG cells, whereas LXR-β confers a basal constitutive effect 
on renin transcription and seems not strictly required for the functional responses of the JG apparatus.
LXR agonists are currently explored as a novel therapy aimed at enhancing reverse cholesterol trans-
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port, thereby inhibiting the progression of atherosclerosis. To our knowledge, no LXR-specific inter-
ventions have been put to test in humans yet. The observation that LXRs function as renin regulators 
may warrant the development of selective modulators of LXR function that circumvent renin activa-
tion while retaining the advantageous effects on lipid metabolism.
Vitamin D receptors
Li et al.7 reported direct evidence that the vitamin D receptor (VDR) acts as a negative regulatory factor 
of renin transcription. VDR-transfected As4.1 cells treated with calcitriol exhibited an almost complete 
abolishment of renin expression. Treatment of wildtype mice with vitamin D also suppressed renin 
expression, whereas in VDR-deficient mice, renin expression was elevated several-fold. So, vitamin 
D yields a direct negative regulatory effect on renin expression through a VDR-mediated mechanism. 
These findings are in agreement with the well-known inverse correlation between plasma vitamin D 
and blood pressure related to decreased plasma renin activity in humans.8
Thyroid hormone receptors
Thyroid hormone receptor (TR) expression is ubiquitous, including in the kidney. Ichihara et al.9 
showed that, in cultured rat JG cells, treatment with thyroid hormones induces renin transcription/
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secretion in a dose-dependent fashion. The same group described 3 candidate thyroid hormone re-
sponse elements (figure 1) located in the human renin gene and showed that, in CaLu-6 cells, thyroid 
hormones stimulate the transcription of the human renin gene.10 In vivo, plasma renin activity and 
renal renin expression are significantly reduced in hypothyroid rats and elevated in hyperthyroid rats.11 
Hyperthyroidism-induced cardiac hypertrophy is accompanied by activation of the cardiac RAAS with 
a significant upregulation of renin mRNA in the kidney.12 Taken together, several lines of evidence sug-
gest that TRs function as positive regulators of renin transcription.
Peroxisome proliferator-activated receptors
Pharmacological targeting of peroxisome proliferator-activated receptors (PPARs; fibrates and thiazoli-
dinediones) has been tested in the treatment of dyslipidemia, diabetes, and established cardiovascu-
lar diseases, such as heart failure and myocardial infarction. The 2 isoforms of PPAR are discussed in 
detail below.
Several animal studies have suggested a role for PPAR-α in the control of renin expression. PPAR-α-
deficient mice put on a high-fat diet are protected from the development of hypertension.13 Mice de-
ficient for both the low-density lipoprotein receptor and PPAR-α have been used to elucidate the role 
of PPAR-α in the development of glucocorticoidrelated insulin resistance.14 In the absence of PPAR-α, 
mice were normotensive and euglycemic, despite dexamethasone treatment. When hepatic PPAR-α 
expression was restored by gene transfer, it not only reinduced hyperglycemia, but also increased 
plasma renin activity, blood pressure, sympathetic nervous activity, and renal sodium retention. Simi-
lar results were obtained in PPAR-α deficient Tsukuba hypertensive mice.15 Tsukuba hypertensive mice 
carry the human renin and angiotensinogen genes and serve as a model of Ang II-mediated hyperten-
sion. PPAR-α deficiency in Tsukuba hypertensive mice decreases plasma renin concentration by ~50% 
and prevents hypertension and myocardial hypertrophy. These observations are supported by obser-
vations made in spontaneously hypertensive rats16 and healthy, human volunteers.17 The exact role of 
PPAR-α in the regulation of blood pressure remains unclear, because several other studies conducted 
in various rat models of hypertension have provided inconsistent results.18,19 It is currently not known 
whether renin activation associated with PPAR-α activation is a direct transcriptional effect of PPAR-α 
or if it should be regarded as a secondary phenomenon, attributable to concomitant blood pressure 
reduction or other ancillary effects of PPAR agonists (eg, antiinflammatory and antiproliferative effects 
on the vasculature or increased sympathetic activity). 
Activation of PPAR-γ signaling has been consistently shown to lower blood pressure in various animal 
models and in human studies, at least in part through direct vascular effects.20–23 However, contro-
versy remains concerning the mechanism of how PPAR-γ influences blood pressure regulation. In an 
in vitro study using CaLu-6 cells, it was shown that activation of PPAR-γ both by endogenous and 
pharmacological agonists, causes a significant increase in renin transcription.24 In a small clinical study, 
the PPAR-γ agonist pioglitazone increased plasma renin levels in humans.25 Overall, there is scarce 
evidence suggesting that PPAR-γ is a candidate regulator of JG cell function; further studies should 




So far, the specific role of the estrogen receptors and progesterone receptors in renin expression has 
not been addressed directly. Renin levels fluctuate with the menstrual cycle, suggesting that estrogen 
and progesterone are regulators of renin transcription. In cultured human chorion cells, progesterone, 
estradiol, testosterone, and aldosterone all affect renin expression levels.26 Estradiol and progester-
one seem to synergistically increase renin expression, because the combined treatment with both 
completely restores renin expression in ovariectomized rats.27 Prorenin and renin are released from 
placental cytotrophoblastic tissue.28 This release occurs in parallel with other placental hormones but 
does not appear to be regulated by steroid receptors, human chorionic gonadotrophin, intracellular 
calcium, or cAMP. Therefore, (pro)renin release from placenta may in fact be regulated in a different 
fashion from renal renin release, eg, by local factors, such as estrogen and progesterone.
Renin receptor
In 2002, a human renin/prorenin receptor was been cloned, which specifically binds renin and pro-
renin.29 Binding of renin to its receptor increases the catalytic activity of renin, and binding of prorenin 
renders prorenin enzymatically active, comparable to renin. Although studies revealing transcription 
mechanisms of the renin receptor are currently underway,30 thus far no “classical” NHRs have been 
identified as transcription factors for the renin/prorenin receptor.
NHRS AND ANGIOTENSINOGEN
Presently, only TRs, PPARs, and estrogen receptors have been implicated in angiotensinogen transcrip-
tional activation and will be discussed below.
Thyroid hormone receptors
The thyroid hormone is a positive regulator of angiotensinogen. Hyperthyroidism, induced by treat-
ment with thyroid hormone (T3), causes an increase of plasma angiotensinogen by 85% in rats.31 In 
parallel, hypothyroidism results in a 71% decrease of plasma angiotensinogen levels. Similar results 
were found in vitro.32 T3 treatment causes upregulation of angiotensinogen transcription in the hu-
man hepatic cell line HepG2. We speculate that the well-described effects of thyroid hormones on 
blood pressure can partially be explained through regulation of angiotensinogen expression and con-
sequent activation of the RAAS.
Peroxisome proliferator-activated receptors
PPAR-α acts as a positive regulator of angiotensinogen transcription. In contrast to HepG2 cells, HeLa 
cells treated with the PPAR-α agonist bezafibrate displayed activation of the angiotensinogen promot-
er.33 This difference between HepG2 and HeLa cells might be explained by the presence of hepatocyte 
nuclear factor-4 in HepG2. Hepatocyte nuclear factor-4 binds to the same responsive region of the 
angiotensinogen promoter as PPAR-α. Hepatocyte nuclear factor-4 is not present in the cervical cell 
line HeLa, and cotransfaction of hepatocyte nuclear factor-4 expression in HeLa cells attenuated the 
activation of the angiotensinogen promoter by bezafibrate.
A dominant-negative form of the PPAR-γ gene was cloned to create a transgenic mouse strain.34 The 
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used mutation was equivalent to the P467L mutation in humans causing severe insulin resistance and 
hypertension. The mouse strain did not develop high blood pressure nor increased kidney renin mRNA 
content. However, upregulations of angiotensinogen and the angiotensin type 1 receptor (AT
1
R) were 
reported. Further research in these mice revealed an increased expression of angiotensinogen in their 
subcutaneous adipose tissue, suggesting a role for PPAR-γ in blood pressure regulation, via the RAAS, 
by modulating angiotensinogen expression in fatty tissue.
Steroid hormone receptors
Early studies demonstrated that estrogens and glucocorticoids can regulate hepatic angiotensinogen 
production.35 Estrogen treatment results in a prompt and significant upregulation of angiotensinogen 
mRNA in rodent liver cells.36 Similar findings have been reported in humans, where women receiving 
oral contraceptives or estrogen replacement therapy develop increased circulating angiotensinogen 
and Ang II levels.37 Overall, the effects of estrogen receptor on angiotensinogen are potentially impor-
tant in the pathophysiology of hypertension in susceptible women and should be considered when 
contraceptive or hormone replacement regimens are prescribed.
NHRS AND ANGIOTENSIN RECEPTORS
The effects of Ang II are mainly mediated via 2 plasma membrane receptors, AT
1
R and angiotensin 
type 2 receptor (AT
2
R). Most effects of Ang II are mediated by the AT
1
R, including an increase of arte-
rial blood pressure, aldosterone secretion, and adverse cardiac and renal remodeling. Rodents express 
2 subtypes of the AT
1
R (A and B), whereas humans express only 1 subtype. AT
2
R is expressed at high 
levels in fetal tissues and decreases rapidly after birth. Although the exact function of AT
2
Rs is less well 
understood than that of the AT
1




R –mediated effects. We discuss 
the influence of PPARs and steroid hormone receptors on AT
1




The role of PPARs in AT
1
R expression is well established. It has been convincingly shown that the 
expression of AT
1
R s is decreased by PPAR-γ agonists in rat vascular smooth muscle cells,38 leading to 
functional inhibition of Ang II-induced cell proliferation via AT
1
R s. Functionally, Diep et al.39 showed 
that treatment with the PPAR-γ activators rosiglitazone and pioglitazone attenuated the detrimental 
effects of Ang II infusion in rats. Development of hypertension, small resistance artery remodeling, 
endothelial dysfunction, proinflammatory mediators, and upregulation of AT
1
R s, all of which are in-
creased by Ang II infusion, were blunted in blood vessels of rats treated with rosiglitazone or piogli-
tazone. Diep et al.39 furthermore, showed that PPAR-γ ligands are capable of increasing AT
2
R expres-
sion on a protein level. These findings are consistent with the significant increase in myocardial AT
2
R 
mRNA found in rosiglitazone-fed rats subjected to an ischemia-reperfusion model.40 Whereas in this 
model AT
1
R mRNA expression was reduced after rosiglitazone treatment, AT
2
R mRNA expression was 
increased by >100-fold.
Cross-talk between angiotensin receptors and PPAR-γ is, thus, relevant. This is further underscored 
by the observation that some angiotensin receptor blockers, such as telmisartan and irbesartan are in 
fact partial PPAR-γ agonists.41 The influence of PPAR-α activator docosahexaenoic acid (DHA) has also 
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been investigated in Ang II-infused rats.42 Like activation of PPAR-γ activation of PPAR-α also attenu-
ated the damaging effects of Ang II infusion in rats, resulting in reduction of Ang II-induced oxidative 
stress, expression of inflammatory mediators, blood pressure, endothelial dysfunction, and remodel-
ing of small resistance arteries. The potential clinical implications of the interaction between PPARs 
and the AT
1
R is discussed in detail below.
Steroid hormone receptors
Sex hormones, especially estrogens, modulate the expression of angiotensin receptors. Estrogen at-
tenuates AT
1
R mRNA, but increases AT
2
R gene expression in rat cardiac fibroblasts.43 In line with this, 
increased AT
1
R expression was found in estrogen treated ovariectomized rats and cell cultures of rat 
smooth muscle cells.44 Later, this group showed that progesterone addition to smooth muscle cell 
cultures upregulated AT
1
R expression.45 It may be speculated that the contrary effects of female sex 
hormones on angiotensin receptor expression could be involved in the changes in arterial pressure 
during the menstrual cycle and perhaps also postmenopausal.
POTENTIAL CLINICAL IMPLICATIONS
The discussed data suggest that modulation of NHR activity comodulates RAAS activity. Large-scale 
clinical studies with NHR agonists have been conducted or are underway, with potential clues on the 
role of NHRs in cardiovascular disease. Specific agonists of PPAR-α, PPAR-γ, VDR, and steroid hormone 
receptors have been put to trial, whereas other agonists are yet to enter the clinical arena. Unfortu-
nately, most clinical trials did not include end-points directly linked to the RAAS, such as plasma renin 
activity or angiotensin- converting enzyme activity. We will discuss the limited data available.
Vitamin D receptors
Vitamin D acts as a negative regulator of renin and might consequently reduce cardiovascular mor-
bidity and mortality. Currently, no large-scale mortality trials have tested the efficacy of vitamin D in 
reducing events in patients with established cardiovascular disease. Some clues are available from 
trials in patients with end-stage renal disease (ESRD), when vitamin D is primarily prescribed to treat 
secondary hyperparathyroidism.
In a small study, analyzing 242 chronic hemodialysis patients, patients treated with alfacalcidol (a vita-
min D analogue) had a significantly lower risk of cardiovascular mortality than patients with no vitamin 
D treatment.46 In fact, several observational studies indicate that there may be a protective effect of 
vitamin D treatment against cardiovascular disease. This claim is hitherto restricted to hemodialysis 
patients with ESRD whose main cause of death is cardiovascular. We postulate that in patients with 
low serum vitamin D levels, and who are at risk for cardiovascular disease, the use of oral vitamin D 
substitutes may reduce the risk for future cardiovascular events.
Peroxisome proliferator-activated receptors
PPAR-α agonists have been primarily tested in patients with hypertriglyceridemia and end-points in 
such studies typically were coronary events and death. The clinical use of fibrates preceded the identi-
fication of PPAR-α as a nuclear receptor, harboring potential ancillary effects beyond lipid lowering. As 
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such, clinical trials with PPAR-α agonists could be revisited for clues regarding the impact of presum-
able PPAR-α activation on RAAS activity. There are observations that support the notion that other 
effects than lipid-lowering effect alone play an important role. For instance, in the Helsinki study, a 
paradoxical increase in noncoronary death was observed.47 However, to our knowledge, in large scale 
trials with PPAR-α agonists, such as the Helsinki Heart Study, the Veteran’s Administration-HDL Inter-
vention Trial (VA-HIT),48 and the FIELD,49 no analyses were conducted with regard to RAAS activity. 
PPAR-γ agonists (thiazolidinediones) exert beneficial effects on the vasculature, including decreased 
carotid artery intima-medial thickness,50 improved endothelial function, and decreased inflamma-
tion.51 Because the RAAS is a dominant player in vascular remodeling, we speculate on some effects 
to be conferred via the RAAS. In previous sections, we discussed experimental data that show the 
interaction between PPAR-γ and the RAAS. This interaction is predominantly at the level of the AT
1
R. 
Some angiotensin receptor blockers are partial PPAR-γ agonists, whereas treatment with glitazones 
can block Ang II-mediated effects.52 Some metabolic effects of angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers, including a reduction of new-onset diabetes, as seen in the 
Heart Outcomes Prevention Evaluation53 and the Losartan Intervention for Endpoint Reduction in Hy-
pertension,54 are suggestive for the existence of PPAR-γ-like effects of RAAS inhibition.
Several large-scale randomized, controlled trials with PPAR-γ agonists have been completed recently. 
The Prospective Pioglitazone Clinical Trial in Macrovascular Events55 showed rather favorable out-
comes, such as a decrease in recurrent myocardial infarction and a decrease in recurrent stroke. The 
Diabetes Reduction Approaches With Ramipril and Rosiglitazone Medications Study established a de-
crease in progression to diabetes in prediabetic patients (with impaired glucose tolerance and/or im-
paired fasting glucose) in rosiglitazone-treated patients.56 Unfortunately, none of these trials reported 
any parameters of RAAS activity.
These outcomes may suggest that PPAR-γ agonists decrease cardiovascular events over time; how-
ever, this remains speculative. Recently, PPAR-γ agonists have come under fire because of claims that 
they may increase rather than decrease the risk of myocardial infarction.57 Although the limitations of 
this meta-analysis have been pointed out by its authors and by others,58 controversy remains concern-
ing the safety of thiazolidinedione treatment.
From the trials with PPAR agonists, it becomes clear that the theoretical working profile is not paral-
leled with a (solely) beneficial clinical efficacy. Likely, the effects that PPARs exert are more global that 
we currently understand: the beneficial effects may not outweigh adverse effects. We suggest putting 
combinatorial therapies with RAAS-inhibitors and PPAR-γ agonists to test in future studies, because 
from the theory this might be more efficacious than either therapy alone.
Perspectives
NHRs have emerged as a class of receptors with a wide array of physiological effects pertaining to 
fatty acid, lipid, and carbohydrate metabolism but also to other pathways, such as inflammation, cel-
lular proliferation, and vascular remodeling. These processes are pivotal in cardiovascular disease, and 
pharmacological targeting of NHRs might provide a novel and promising treatment approach. Some 
agonists of NHRs have entered the clinical arena, showing a promising efficacy and safety profile. 
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Because the RAAS is a main player in cardiovascular homeostasis, any effects of NHRs on RAAS activ-
ity may likely affect its working and safety profile. In this review, we discussed the levels of interac-
tion between some NHRs and the RAAS. Experimental studies have partially elucidated the molecular 
mechanisms of the regulation of the RAAS by NHRs. It is speculated that, by exploring the clinical value 
of NHRs, the effect on RAAS activation may have important repercussions for their efficacy and safety. 
We, therefore, recommend that future clinical studies include analyses of RAAS activation. 
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SUMMARY
Liver X receptors (LXRs) are nuclear hormone receptors that act as ligand-activated transcription fac-
tors.1 They are critically involved in cholesterol metabolism2 and their natural ligands are oxysterols; 
oxidized cholesterol derivatives.3 There are two known isoforms of LXRs; LXR-α (mainly expressed in 
liver, spleen, intestine, macrophages, heart and kidney) and LXR-β (expressed ubiquitously).4 Over 
the last decade, research on LXRs was mainly focused on their role in cholesterol metabolism. It was 
discovered that LXRs play a crucial role in the process of ‘reverse cholesterol metabolism’; the efflux 
of cholesterol from peripheral tissues towards the liver for excretion.2 More recent studies show that 
LXRs also exert pleiotropic properties. They have been shown to attenuate proliferative pathways,5 
blunt inflammatory responses,6 and influence the renin-angiotensin-aldosterone system (RAAS).7 
Metabolic and inflammatory pathways highly influence the onset en development of cardiovascular 
disease. Both pathways are controlled by complex mechanisms, in which LXRs play a critical role.8 
However, knowledge of the direct effects of LXRs on the cardiovascular system remains scarce. In this 
thesis, several models of cardiac remodeling and cardiac failure have been used to investigate the 
role of LXRs in the pathophysiology of these conditions. Chapter 1 provides an extensive overview 
of previous studies on LXR functioning in the cardiovascular system, extended with our own findings 
described in detail in the following chapters.
The RAAS
The RAAS has been identified as the main system involved in blood pressure regulation, renal hemody-
namics, and sodium volume homeostasis. Furthermore, the RAAS directly affects vascular and cardiac 
remodeling through proliferative and inflammatory signaling. Pharmacological targeting of the RAAS 
is a consolidated and evidence-based approach in the treatment of various aspects of cardiovascu-
lar disease. An exploding number of recent studies have provided novel insights into nuclear recep-
tor biology in relation to cardiovascular (patho)physiology. Chapter 6 reviews the potential effects of 
nuclear hormone receptors (NHRs) on the RAAS, summarizing the extensive body of evidence from 
experimental, animal, and clinical studies, suggesting that NHRs and the RAAS are closely intertwined.
A specific interaction of LXRs and the RAAS is described in chapter 2. Here we report that activation 
of LXR with the specific agonist T09 leads to a decrease in renal and cardiac RAAS activation due to 
isoproterenol (ISO) infusion. The LXR agonist T09 blunts ISO induced increases in renin, angiotensin 
converting enzyme (ACE) and angiotensin type 1 receptor (AT
1
R) expression in vitro and in vivo, and 
competes with the binding of LXR-α to the CNRE in the renin promoter. The observed effects are com-
pletely absent in LXR-α-/- mice, suggesting LXR-α dependency. On the basis of these data, we postulate 
that LXR agonists may serve as inhibitors of the RAAS. 
Chapter 2 describes the first long-term in vivo study focussing on LXR signalling in the RAAS. Previ-
ously, LXR-α was denoted as a cAMP-dependent regulator of renin in vitro,9 and Morello et al.7 showed 
that immediately after administration of a synthetic agonist, LXR-α regulates renin transcription in 
vivo. The transcriptional regulation of ACE is largely unknown, whereas regulation of AT
1
R is tight, 
complex and well described.10 Our findings of decreased renal AT
1
R mRNA expression are in line with 
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those of Imayama et al.,11 who demonstrated LXR to be a negative regulator of AT
1
R in cultured vas-
cular smooth muscle cells. In line with this, Leik et al. showed that LXR activation by GW3965 leads to 
reduced angiotensin II-mediated pressor responses in rats.
After identifying LXRs as negative regulators of the RAAS, we hypothesized that LXR activation protects 
the heart from disadvantageous effects of hypertension.
Cardiac remodeling
Cardiac hypertrophy
The hypothesis that LXR activation protects the heart from disadvantageous effects of hypertension 
was tested in chapter 3. This study demonstrates that the activation of LXRs attenuates cardiac hyper-
trophy. Using an in vitro model of cultured cardiomyocytes, we show that LXR activation attenuates 
cardiomyocyte hypertrophy. In addition, we show in an in vivo model of cardiac hypertrophy that LXR 
activation decreases cardiac remodeling along with hypertension and improves diastolic parameters. 
These effects were substantially blunted in LXR-α-/- mice, indicating that these are LXR-α- dependent 
effects. 
Recently, Wu et al.12 reported that LXR activation in cultured rat cardiomyocytes reduces hypertrophy 
in response to angiotensin II treatment. Here we confirm and extend these results; we proof that this 
is indeed a LXR-dependent effect. Employing siRNA interference, which causes knock-down of LXR 
expression, we showed that the attenuating effect of T09 is absent in this condition.
To corroborate these in vitro findings in vivo, we employed a mouse model to test the effects of LXR 
activation on myocardial hypertrophy. Here we show that also in this model, T09 exerts anti-hypertro-
phic effects. In addition to a decrease in cardiac remodeling after AC surgery, we observed a decrease 
in blood pressure following treatment of wildtype mice with T09, which is in line with our findings 
described in chapter 2.
The mechanism through which LXRs exert their anti-hypertrophic effect is still under investigation. It 
has been observed in clinical studies that changes in left ventricular hypertrophy (LVH) may not be 
exclusively explained by the blood pressure lowering effect of a drug.13 In addition to the blood pres-
sure lowering effect, direct LXR activation in the myocardium may also explain the observed changes 
in LVH. Several in vitro studies have described anti-proliferative effects of LXR activation in various 
cell types, including VSMCs,5 pancreatic islet β cells,14 keratinocytes,15 and breast cancer cells.16 Our 
study demonstrates that LXR activation also inhibits cardiomyocyte hypertrophy. Wu et al.12 recently 
suggested that nuclear factor (NF)-κB may confer the antihypertrophic effects of LXR-α in cardio-
myocytes. However, other cardiac transcription factors such as Sp1 or other kinases such as mitogen-
activated protein kinase (MAPK) may be controlled by LXRs as well and thus be involved in remodel-
ing pathways of the hypertrophic heart. We show here that like in other tissues or cell types,17 the 
transcription factor sterol regulatory element binding protein (SREBP)-1c is increased in the hearts of 
mice treated with T09. SREBP-1c has been shown to be involved in parasympathetic responses in the 
murine heart,18 however its role in the development of cardiac remodeling remains to be elucidated. 
In addition, we also show an increase in mRNA expression of other specific target genes of LXR, e.g. 
ATP-binding cassette transporter (ABC)A1 and ABCG1, combined with an increase in protein levels of 
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ABCG1. These changes in specific LXR target genes show increased activity in the myocardium of LXR 
as a transcription factor. Together with the activation of systemic LXR targets (as shown by serum cho-
lesterol increases), these data strongly support the notion that LXR specific pathways are activated by 
T09 treatment, both systemically and locally (in the myocardium).
Myocardial infarction
In chapter 5 we show that activation of LXR results in attenuated cardiac hypertrophy after a myocar-
dial infarction (MI). This was demonstrated by the attenuation of LVH and LV dilatation observed in 
T09-treated mice compared to the MI mice without T09 treatment. Also, the decrease in wall thicken-
ing after MI was attenuated in MI+T09 mice compared to MI mice. In addition, fractional shortening 
and ejection fraction were higher in MI+T09 mice compared to MI mice. These results provide further 
proof for a potential role for LXR activating drugs with the aim to prevent cardiac remodeling. 
In this study, we did not perform additional tissue analyses that would provide mechanistic clues as 
to how LXR exerts its cardio-protective effects. It seems plausible that LXR attenuates the complicated 
process of post-MI cardiac remodeling via various pathways, as LXR influences so many (pleiotropic) 
processes. Direct actions on cardiomyocytes,19 macrophages,6 and the RAAS7 enable LXRs to influ-
ence cardiac remodeling, inflammatory responses and blood pressure homeostasis. Because all these 
processes are critically involved in the process of cardiac remodeling post-MI, further research is war-
ranted to establish through which mechanism(s) LXR influences this process. 
Statins
In chapter 4 we studied the interplay of statins with LXRs. Here we describe that in a model of pressure 
overload, treatment with pravastatin attenuates LVH in wildtype mice but not in LXR-α-/- mice. Since 
we have previously showed that activation of LXRs by a synthetic agonist attenuates the development 
of LVH,19 these data strongly suggest an important role for LXRs in the pathway through which statins 
are able to attenuate the development of LVH. 
That statins are able to attenuate LVH has been known for some time (reviewed in20), but it remains 
unclear through which mechanism this effect is exerted. The data described in chapter 4 (as well 
as earlier publications21) show that in wildtype mice, statin treatment results in lowered MAP. This 
suggests that the attenuation of LVH in these mice might be exerted by the blood pressure lowering 
effects of statins. In LXR-α-/- mice statins did not affect the MAP, showing a crucial role for LXRs in the 
blood pressure lowering effects of statins. Indeed, earlier studies show that activation of LXRs results 
in blunted activation of the RAAS and decreased blood pressure.22,23 
However, as mentioned above, clinical studies show that changes in LVH may not be solely explained 
by the blood pressure lowering effect of a drug.13 Previously we showed that in vitro (so without 
any systemic haemodynamic effects), LXR activation results in attenuation of cardiomyocyte hypertro-
phy.19 In addition we show in chapter 4 that statin treatment directly affects cardiac mRNA expression 
of several target genes of LXR. So on top of its blood pressure lowering effects, statins also directly 
affect LXR target gene transcription in cardiomyocytes. These findings confirm interplay of LXRs and 
statins and suggest that the protective role of statins in the development of LVH is mediated by LXR-α.
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Over the last decade, the knowledge on LXR functioning in (patho)physiological conditions has in-
creased intensively. As inhibitors of inflammatory responses, hypertension, cardiomyocyte hypertro-
phy, etc., LXR agonists may form adequate remedies in the treatment of several cardiovascular dis-
eases. The main challenge remains to exploit these beneficial properties of LXRs while retaining side 
affects of LXR activation, such as hypertriglyceridemia and steatosis hepatic.24 So far, the development 
of isoform, tissue, or gene specific LXR agonists has been proposed as potential solutions for these 
unwanted side effects.25 
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Liver X receptoren (LXRs) zijn nucleaire hormoonreceptoren die de transcriptie van verschillende 
genen induceren. LXRs spelen een belangrijke rol in cholesterolmetabolisme en worden geactiveerd 
door oxysterolen; geoxideerde cholesterol partikels. Er zijn twee isoformen van LXRs bekend: LXR-α 
(voornamelijk tot expressie gebracht in de lever, de milt, de darmen, de macrofagen, het hart en de 
nieren) en LXR-β (wordt in het gehele lichaam tot expressie gebracht). In de afgelopen 10 tot 15 jaar 
heeft het onderzoek naar LXRs zich voornamelijk gericht op de rol van LXRs in cholesterolmetabo-
lisme. Daaruit is duidelijk geworden dat LXRs een belangrijke rol spelen in het zogenaamde reversed 
cholesterol transport, oftewel het transport van cholesterol vanuit weefsels richting de lever. Recente 
studies hebben aangetoond dat LXRs ook een rol spelen in andere fysiologische processen, zoals het 
remmen van ontstekingsreacties en cel proliferatie. Daarnaast is gebleken dat LXRs een remmende 
invloed kunnen uitoefenen op het renine-angiotensine-aldosteron systeem (RAAS), het systeem dat 
de bloeddruk reguleert.
Cholesterolmetabolisme en ontstekingsreacties zijn van grote invloed op de ontwikkeling en het ver-
loop van cardiovasculaire aandoeningen. Beide processen worden gereguleerd door complexe syste-
men, waarin LXRs een belangrijke rol spelen. Het achterliggende mechanisme waarmee LXRs invloed 
uitoefenen op het cardiovasculaire systeem is grotendeels onbekend. In dit proefschrift maken we 
gebruik van verschillende modellen voor cardiovasculaire aandoeningen om de rol van LXRs in de 
pathofysiologie van deze aandoeningen te onderzoeken. Hoofdstuk 1 is een literatuuroverzicht van de 
studies die het functioneren van LXRs in het cardiovasculaire systeem onderzocht hebben, aangevuld 
met onze eigen bevindingen.
Het RAAS
Het RAAS systeem is essentieel in de regulatie van bloeddruk, hemodynamiek van de nieren en ho-
meostase van het extracellulaire volume. Tevens beïnvloedt het RAAS vasculaire en cardiale herstruc-
turering (remodeling) door invloed uit te oefenen op cel proliferatie en ontstekingsreacties. Om deze 
redenen is farmacologisch ingrijpen op het RAAS een effectieve en veelgebruikte methode in de be-
handeling van verscheidene cardiovasculaire aandoeningen. Recent onderzoek biedt nieuwe inzichten 
in de biologie van nucleaire receptoren in relatie tot cardiovasculaire (patho)fysiologie. Deze nieuwe 
inzichten en recente studies worden samengevat in hoofdstuk 6 en laten zien dat er een nauwe sa-
menwerking is tussen nucleaire hormoon receptoren (NHRs) en het RAAS.
Hoofdstuk 2 beschrijft in meer detail de samenwerking tussen LXRs en het RAAS. Hierin beschrijven 
we hoe het activeren van LXRs met de specifieke agonist T09 leidt tot een afname van (door isopro-
terenol (ISO) geïnduceerde) RAAS activering in het hart en de nieren. Deze effecten zijn niet aanwezig 
in muizen die het LXR-α gen niet tot expressie brengen (LXR-α-/- muizen), wat suggereert dat dit effect 
van de agonist LXR-α afhankelijk is. Hoofdstuk 2 is tevens de eerste beschrijving van een langdurige in 
vivo studie naar het activeren van LXRs in het RAAS. Eerdere (in vitro) studies hebben aangetoond dat 
LXR-α in staat is renine transcriptie in vitro te reguleren via een cAMP afhankelijk mechanisme. Tevens 
hebben in vivo studies laten zien dat binnen enkele uren na de toediening van een synthetische LXR 
agonist, LXR-α reninetranscriptie in muizen reguleert. De transcriptionele regulatie van angiotensin 
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converting enzyme (ACE) is grotendeels onbekend, maar de (complexe) transcriptionele regulatie van 
de angiotensine receptor type 1 (AT
1
R) is al grotendeels opgehelderd. In onze studie zien we een 
afname van AT
1
R mRNA expressie in de nieren, wat overeenkomt met eerder gepubliceerde stud-
ies. Zo is al eerder aangetoond dat het activeren van LXRs leidt tot een afname van AT
1
R expressie in 
vasculaire gladde spiercellen in vitro. Een andere studie heeft aangetoond dat het activeren van LXRs 
leidt tot een verlaagde bloeddruk in ratten behandeld met angiotensine II. Aan de hand van de data 
beschreven in hoofdstuk 2 concluderen we dat het activeren van LXRs RAAS activiteit verlaagt, wat zou 
kunnen leiden tot bloeddruk verlaging. Dit leidt tot onze volgende hypothese: het activeren van LXRs 
beschermt het hart tegen de nadelige effecten van hypertensie.
Remodellering van het hart
Hypertrofie van het hart
De hypothese dat het activeren van LXRs het hart beschermt tegen de nadelige effecten van hyperten-
sie hebben we getest in hoofdstuk 3. Deze studie laat zien dat het activeren van LXRs de ontwikkeling 
van cardiale hypertrofie tegengaat. Met behulp van een in vitro studie laten we zien dat het activeren 
van LXRs de hypertrofie van cardiomyocyten tegen gaat. Vervolgens laten we in een muismodel voor 
cardiale hypertrofie zien dat activering van LXRs zowel de ontwikkeling van hypertensie als remodel-
lering van het hart tegengaat. Omdat deze effecten niet zichtbaar waren in LXR-α-/- muizen, lijkt dit een 
LXR-α afhankelijk effecten te zijn.
Onlangs hebben Wu et al. een studie gepubliceerd waarin omschreven wordt dat het activeren van 
LXRs in vitro in ratcardiomyocyten de hypertrofische respons tegengaat na angiotensine II behandel-
ing. In hoofdstuk 3 bevestigen we deze resultaten en breiden ze verder uit door te bewijzen dat dit een 
LXR-afhankelijk effect is. Door gebruik te maken van siRNA, wat een complete blokkade vormt voor 
LXR-expressie, laten we zien dat het remmende effect van T09 zonder LXR-expressie niet aanwezig is.
Vervolgens hebben we onze in vitro bevindingen in vivo getest door gebruik te maken van een muizen-
model om de effecten van het activeren van LXRs op hypertrofie van het hart te testen. We laten zien 
dat in dit model T09 antihypertrofische effecten laat zien. Naast de afname de remodellering van het 
hart, zien we dat de bloeddruk lager is in wildtype muizen die behandeld zijn met T09. Deze bevindin-
gen zijn in overeenstemming met de resultaten omschreven in hoofdstuk 2.
Het mechanisme achter de antihypertrofische effecten van LXR is nog niet volledig opgehelderd. 
Klinische studies hebben laten zien dat effecten op hypertrofie van het linker ventrikel niet alleen door 
bloeddruk verlagende effecten van medicatie kunnen worden verklaard. Naast het bloeddruk verlag-
ende effect van het activeren van LXRs kunnen directe effecten van LXR op het myocardium ook van 
invloed zijn op de ontwikkeling van hypertrofie. Verschillende in vitro studies hebben laten zien dat 
het activeren van LXRs leidt tot verminderde proliferatie van verschillende celtypen. Onze studie laat 
zien dat activering van LXRs in vitro de hypertrofie van cardiomyocyten tegengaat. Recent hebben Wu 
et al. aangetoond dat de antihypertrofische effecten van LXR-α in cardiomyocyten gereguleerd wor-
den door ‘nuclear factor (NF)-κB’. Er worden echter ook andere transcriptiefactoren en kinases in het 
hart tot expressie gebracht die betrokken zijn bij remodelleringsmechanismen, zoals Sp1 en ‘mitogen-









van LXRs. In onze studie laten we zien dat net als in andere weefsels en celtypen, de transcriptiefactor 
‘sterol regulatory element binding protein (SREBP)-1c’ verhoogd tot expressie wordt gebracht in het 
hart na behandeling met T09. De rol van SREBP-1c in de remodellering van het hart is nog grotendeels 
onbekend, maar het is aangetoond dat SREBP-1c betrokken is bij de parasympathische reacties in 
muizenharten. Onze studie laat tevens zien dat de expressie van andere specifieke targetgenen van 
LXR verhoogd is na T09 behandeling, zoals de expressie van ATP-binding cassette transporter (ABC)
A1 en ABCG1. Deze verhoogde expressie van specifieke LXR targetgenen laat zien dat LXR actief is als 
transcriptiefactor in het myocardium. 
Myocardinfarct
Een ander model waarmee we de rol van LXRs in remodellering van het hart onderzocht hebben wordt 
omschreven in hoofdstuk 5. Hier laten we zien dat het activeren van LXRs leidt tot verminderde hyper-
trofie van het hart na een myocardinfarct (MI). Dit uit zich in een vermindering van de verdikking van 
de hartwanden, evenals verminderde dilatatie van het linker ventrikel in de muizen die met T09 be-
handeld zijn, vergeleken met de MI muizen zonder T09 behandeling. Tevens is de fractional shortening 
en de ejectiefractie hoger in MI+T09 muizen vergeleken met MI muizen. Deze resultaten bevestigen 
dat het activeren van LXRs gunstige effecten heeft op de preventie van remodellering van het hart.
In deze studie zijn geen weefselanalyses uitgevoerd om het mechanisme achter de beschermende 
effecten van het activeren van LXRs vast te stellen. Het is aannemelijk dat LXR via verscheidene mecha-
nismen deze effecten op het hart uitoefent, aangezien LXR bij een groot aantal fysiologische processen 
betrokken is. Door beïnvloeding van cardiomyocyten, macrofagen en het RAAS zijn LXRs in staat om re-
modellering van het hart, ontstekingsreacties en bloeddruk homeostase te reguleren. Omdat al deze 
processen een grote rol spelen in het remodelleringsproces van het hart na een MI, is verder onder-
zoek van belang om de betrokken mechanismen waardoor LXRs hun invloed uitoefenen te ontrafelen.
Statines
In hoofdstuk 4 bestuderen we de interactie van statines met LXRs. In dit hoofdstuk beschrijven we dat 
in een model van overdruk op het hart, behandeling met pravastatine hypertrofie vermindert in wild-
type muizen, maar niet in LXR-α-/- muizen. Omdat we eerder hebben aangetoond dat het activeren 
van LXRs de ontwikkeling van hypertrofie van het hart vermindert, suggereert deze data dat LXRs een 
prominente rol spelen in het mechanisme waarmee statines in staat zijn de ontwikkeling van hyper-
trofie te verminderen.
Dat statines in staat zijn hypertrofie van het hart te verminderen is reeds bekend, maar het mechanisme 
waarmee zij dit effect bereiken is tot op heden niet volledig opgehelderd. De data die beschreven wor-
den in hoofdstuk 4 laten (samen met eerdere publicaties) zien dat in wildtype muizen de behandeling 
met statine een bloeddruk verlagend effect heeft. Dit wekt de suggestie dat de verminderde hypertro-
fie van de harten van deze muizen veroorzaakt wordt door de bloeddrukverlagende effecten van deze 
behandeling. In LXR-α-/- muizen had de statine behandeling geen effect op de bloeddruk, wat laat zien 
dat LXR-α een cruciale rol speelt in dit proces. Deze resultaten bevestigen de eerdere studies die laten 
zien dat het activeren van LXRs resulteert in verminderde RAAS activiteit en een verlaagde bloeddruk. 
Echter, klinische studies laten zien dat veranderingen in de ontwikkeling van hypertrofie niet alleen 
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door de bloeddruk verlagende effecten van medicatie verklaard kunnen worden. Eerder hebben we 
al laten zien dat in vitro het activeren van LXRs leidt tot verminderde hypertrofie van cardiomyocyten. 
Tevens laten we in hoofdstuk 4 zien dat statine behandeling een direct effect heeft op de transcriptie 
van specifieke LXR target genen in het hart. Dus naast de bloeddruk verlagende effecten beïnvloedt 
een statinebehandeling de gentranscriptie van specifieke target genen van LXR in cardiomyocyten. 
Deze data bevestigen een interactie tussen LXRs en statines en suggereren dat de beschermende ef-
fecten van statines tijdens de ontwikkeling van hypertrofie afhankelijk zijn van LXR-α.
TOEKOMSTPERSPECTIEVEN
Het laatste decennium is de kennis over het functioneren van LXRs in (patho)fysiologische systemen 
enorm toegenomen. Als remmers van ontstekingsreacties, hypertensie en cardiomyocythypertrofie 
kunnen LXR activerende middelen als adequate remedie dienen in de behandeling van verschillende 
cardiovasculaire aandoeningen. De grote uitdaging blijft om gebruik te maken van deze positieve ei-
genschappen van LXRs terwijl nadelige bijwerkingen van het activeren van LXRs, zoals hypertriglycer-
idemie en steatosis hepatis, gering worden gehouden. Potentiële oplossingen hiervoor zijn de ontwik-
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dit project. Ook de overige stafleden - Pim, Beatrijs, Alexander en Herman - wil ik hartelijk bedanken 
voor hun betrokkenheid en inzet. Regien, bedankt voor je goede adviezen aangaande al het dierwerk. 
Ik vond onze tripjes richting Papendal erg gezellig. Carla, Alma, Audrey en Marjan, hartelijk bedankt 
voor jullie organisatorische hulp. Deze is onmisbaar om een promotietraject met succes te kunnen 
afronden!
Ik ben mijn promotieonderzoek begonnen op de afdeling Klinische Farmacologie. Een aantal oud-
collega’s van deze afdeling wil ik hartelijk bedanken voor hun steun. Antoinet, Marry, Azu, Jan, Alex, 
Jacko, bedankt voor alle gezelligheid, vooral tijdens de koffiemomentjes ’s ochtends vroeg. Dankzij 
jullie voelde ik me direct welkom op de afdeling, bedankt hiervoor! Rob, Anton, Leo en Dick, bedankt 
voor jullie bijdrage en gastvrijheid tijdens de ‘mollab-lunches’ en de refereeravonden. Ook de mede 
PhD-studenten van de KF wil ik graag bedanken voor hun bijdrage aan de goede sfeer tijdens onze 
‘social events’. Bernadet (Detje) en Hiddo, fijn dat jullie er waren op de gezellige maar ook de lastige 
momenten. Iryna, Peter, Maggie, Hjalmar, Roelien, veel succes met de afronding van jullie projecten. 
Ardy, dankjewel voor al je adviezen (op allerlei vlakken!).
De drijvende kracht achter experimenteel onderzoek bestaat ook in mijn geval uit een aantal hard-
werkende mensen op het lab. Linda, je hebt je vanaf het begin af aan erg betrokken gevoeld bij mijn 
project en er bergen werk voor verzet. Hartelijk bedankt hiervoor. Johan, dankjewel voor onze gezel-
lige ECHO-momentjes. Het is een mooi artikel geworden! Bibiche, bedankt voor de ‘finishing touch’ 
van mijn laatste experimenten. Bianca, Janny, Silke, Martin en natuurlijk ook Annet en Germaine, 
bedankt voor jullie gezelligheid, steun, adviezen en betrokkenheid.
Een groot deel van mijn tijd als AIO heb ik doorgebracht op het CDL. Dankzij alle lieve medewerkers 
daar heb ik ontzettend veel plezier gehad in het ‘dierwerk’ en blijf ik dit graag doen in de toekomst. 
Allemaal hartelijk bedankt hiervoor! Hester, Marcia en Annet, fijn om het werk te beginnen met een 
praatje bij de balie. Arie, Wiebe, Flip, Catriene en Miriam, bedankt voor raad en daad waar nodig. 
Yvonne, Maurice, Diana, Harm, hartelijk bedankt voor de liefdevolle verzorging van mijn ‘stinkies’. 
Annemieke, André, Michel, Pieter, Natascha, Angela, Hilda, Ar, Silvia, Harm, Ralph, Mark, Annemiek, 
Andrea, bedankt voor alle gezelligheid en vrolijkheid. En natuurlijk Ramon, hartelijk bedankt voor je 
oprechte interesse in mijn werk. Heel veel succes met je ambities, ik weet zeker dat je succesvol zult 
zijn!
Promoveren doe je nooit alleen, maar ook zelden op één afdeling. Marcel, hartelijk bedankt voor al 
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je hulp bij het uitvoeren van de MRI-scans. Heel fijn dat je op al die onmogelijke tijdstippen voor me 
klaarstond! Arjen, dankjewel voor het ad hoc bijspringen bij lastige operaties. Nuttig èn gezellig! Een 
aantal mensen van de Kindergeneeskunde wil ik hartelijk bedanken voor hun samenwerking. Juul, 
dankjewel voor je hulp bij het ‘muiswerk’. Torsten en Esther, leuk dat onze projecten af en toe zo dicht 
bij elkaar kwamen. Esther, fijn dat ik bij jou heb mogen afkijken hoe alles in z’n werk gaat tijdens een 
promotietraject. Ik blijf nog steeds hopen op een ‘dubbeldate’!
De afgelopen jaren heb ik het geluk gehad om een heel fijne groep ‘lotgenoten’ om me heen te hebben, zeker 
een essentieel onderdeel van een geslaagd promotietraject. Hisko, ‘roomie’, fijn dat we dit traject samen 
hebben doorlopen. Ik vind het een eer dat ik je paranimf mag zijn. Heel veel geluk in Rotterdam, samen 
met je lieve vrouw!          
 Liza, onze vrolijke noot! Bedankt voor je enorme inzet om het werk tot iets gezelligs te maken. Ik heb 
erg genoten van AIOweekenden, eetafspraakjes, drankafspraakjes, congres-shop-dans-combinaties 
en eigenlijk gewoon van je aanwezigheid. Laura en Anne-Margreet, bedankt voor onze gezellige eet-
dates, een mooie traditie. Volgende keer in Rotterdam? Jardi, ik weet het nog steeds zeker; je bent ge-
woon een bioloog. En dat is een groot compliment! Leonie, Mariusz, Willem-Peter, Lennaert, Michael, 
Reinout en Frank, dank jullie voor alle gezelligheid. Succes met de jullie (laatste) loodjes. Wardit en 
Megan, jullie beginnen pas aan jullie eerste loodjes, maar ik heb er alle vertrouwen in dat jullie er een 
succes van zullen maken. Net zoals ik er vertrouwen in heb dat Megan dit binnenkort zelf kan vertalen! 
Dear Lili and Bo, you have been great roommates. Thank you for our nice talks and for some insights in 
Chinese culture and habits. Dear Meimei, thank you for your everlasting cheerful mood! It’s nice hav-
ing you as a colleague, good luck finishing up your project. Dear Hong Juan, we haven’t talked much 
yet, but I wish you best of luck in your work here. And then of course the ones who have successfully 
finished their projects but just couldn’t get enough: the postdocs! Dear Irene and Hasan, it’s great to 
have you in our department. Thanks for your positive contribution to the work atmosphere.
Mijn lieve nimfjes, waar zou ik zijn zonder jullie! Lieve Bina, je bent m’n steun en toeverlaat ge-
weest gedurende dit project, maar ook daarbuiten. Ik ben ontzettend trots op je wat je al-
lemaal bereikt hebt! Dankjewel voor je betrokkenheid, je eerlijkheid en je vriendschap (zelfs 
trans-Atlantisch onverminderd). Geweldig dat je voor me naar Nederland komt, ik mis je!   
Lieve Inge (Vreeswijk), ik weet oprecht niet hoe alles gelopen zou zijn als jij niet op onze afdel-
ing was gekomen. Dankjewel dat je me er doorheen gesleept hebt en dat je ook nog eens een 
van mijn beste vriendinnen geworden bent. Je bent een fantastisch persoon en ik ben ontzettend 
trots op wat jij allemaal hebt weten te bereiken! Ik hoop dat we nog vaak de mogelijkheid 
krijgen samen te werken, maar bovenal dat ik nog lang van je vriendschap mag genieten.   
Lieve Maaike, de rol van ‘reserve paranimf’ lijkt misschien wat dubieus, maar jij hebt deze met glans weten 
te vervullen. Dankjewel voor al je hulp de afgelopen jaren, je gezellige aanwezigheid en je steun op de min-
dere momenten.           
Lieve Femke, we kennen elkaar nog niet zo lang, maar inmiddels heb jij ook zeker een plekje in deze 
alinea verdiend. Als ongekroonde ‘reserve reserve paranimf’ heb je veel puntjes op i’s gezet voor me, 
dankjewel hiervoor! Je bent een absolute aanwinst voor de afdeling(en)!
Een aantal lieve vrienden en vriendinnen mogen ook zeker niet in dit dankwoord ontbreken. Lieve 
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DANKWOORD
Fleur en Aleida (en in deze context natuurlijk ook Sabina nogmaals), onze Den Haspel weekendjes 
hebben zeker bijgedragen aan mijn welbevinden tijdens mijn AIO-tijd. Fleur, volgende feestje bij jou! 
Lieve Michael (Mikey Mike), niets werkt zo goed om de moed erin te houden als uitgebreid met jou 
lunchen of shoppen (in de baas z’n tijd!). Lieve Miriam en Antje, wat heerlijk om vriendinnen te heb-
ben met wie ik net zo hard kan lachen als huilen. Dank jullie voor al jullie steun en betrokkenheid, jullie 
zijn goud waard!
Lieve papa en mama, jullie hebben voor mij een veilige, solide basis gevormd van waaruit ik alles kan 
ondernemen. Dank jullie voor jullie steun, de kansen die jullie me gegeven hebben en het veilige van-
gnet dat jullie vormen indien nodig. Lieve Alja, grote zus, dankjewel dat je altijd voor me klaarstaat in 
vele opzichten en dat je altijd met me meeleeft. Ik wens jou en Richard heel veel geluk en liefde in de 
toekomst, fijn om een grote broer te hebben! Want lieve Jeroen (lief Beertje), ondanks dat je inmid-
dels een kop groter en misschien ook wel een stuk wijzer bent dan ik ben, blijf je toch altijd mijn kleine 
broertje. Dankjewel voor je nuchterheid, je relativeringsvermogen en je humor. Volgend feestje vieren 
we jouw Meesterstuk!
Lieve Marc, je bent zo’n bijzonder persoon dat elke omschrijving van jou je tekort zou doen. Geweldig 
hoeveel steun, hulp, geduld en begrip ik van je mocht krijgen gedurende de afgelopen jaren. Bedankt 
voor wie je bent en voor wie je voor mij wilt zijn. Satje Satje!!





